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A B S T R A C T
Background
Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate
in the inner ear labyrinth or its neural connections. It is a commonly experienced symptom and can cause significant problems with
carrying out normal activities. Betahistine is a drug that may work by improving blood flow to the inner ear. This review examines
whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes.
Objectives
To assess the effects of betahistine in patients with symptoms of vertigo from different causes.
Search methods
The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CEN-
TRAL 2015, Issue 8); PubMed; EMBASE; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published
and unpublished trials. We also contacted manufacturers and researchers in the field. The date of the search was 21 September 2015.
Selection criteria
We included randomised controlled trials of betahistine versus placebo in patients of any age with vertigo from any neurotological
diagnosis in any settings.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcome was the proportion of patients with
reduction in vertigo symptoms (considering together the intensity, frequency and duration those symptoms).
Main results
We included 17 studies, with a total of 1025 participants; 12 studies were published (567 patients) and five were unpublished (458
patients). Sixteen studies including 953 people compared betahistine with placebo. All studies with analysable data lasted three months
or less. The majority were at high risk of bias, but in some the risk of bias was unclear. One study, at high risk of bias, included 72 people
with benign paroxysmal positional vertigo (BPPV) and compared betahistine with placebo; all patients also had particle repositioning
manoeuvres. The studies varied considerably in terms of types of participants, their diagnoses, the dose of betahistine and the length of
time it was taken for, the study methods and the way any improvement in vertigo symptoms was measured. Using the GRADE system,
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we judged the quality of evidence overall to be low for two outcomes (proportion of patients with improvement and proportion with
adverse events).
Pooled data showed that the proportion of patients reporting an overall reduction in their vertigo symptoms was higher in the group
treated with betahistine than the placebo group: risk ratio (RR) 1.30, 95% confidence interval (CI) 1.05 to 1.60; 606 participants; 11
studies). This result should be interpreted with caution as the test for statistical heterogeneity as measured by the I2 value was high.
Adverse effects (mostly gastrointestinal symptoms and headache) were common but medically serious events in the study were rare and
isolated: there was no difference in the frequency of adverse effects between the betahistine and placebo groups, where the rates were
16% and 15% respectively (weighted values, RR 1.03, 95% CI 0.76 to 1.40; 819 participants; 12 studies).
Sixteen per cent of patients from both the betahistine and the placebo groups withdrew (dropped out) from the studies (RR 0.96, 95%
CI 0.65 to 1.42; 481 participants; eight studies).
Three studies looked at objective vestibular function tests as an outcome; the numbers of participants were small, techniques of
measurement very diverse and reporting details sparse, so analysis of this outcome was inconclusive.
We looked for information on generic quality of life and falls, but none of the studies reported on these outcomes.
Authors’ conclusions
Low quality evidence suggests that in patients suffering from vertigo from different causes there may be a positive effect of betahistine
in terms of reduction in vertigo symptoms. Betahistine is generally well tolerated with a low risk of adverse events. Future research into
the management of vertigo symptoms needs to use more rigorous methodology and include outcomes that matter to patients and their
families.
P L A I N L A N G U A G E S U M M A R Y
Betahistine for symptoms of vertigo
Review question
Do patients suffering from vertigo from different causes benefit from the drug betahistine?
Background
Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in
the inner ear balance organ or its connections to the brain. It is a commonly experienced symptom and can cause significant problems
with carrying out normal activities. Betahistine is a drug that may work by improving blood flow to the inner ear. This review examines
whether betahistine is more effective than a placebo (sham medicine) at treating symptoms of vertigo from different causes in patients
of any age.
Study characteristics
We included 17 studies, with a total of 1025 participants. Sixteen studies including 953 people compared betahistine with placebo;
the studies were at high to unclear risk of bias. All studies with analysable data lasted three months or less. One study, at high risk of
bias, included 72 people with benign paroxysmal positional vertigo (BPPV) and compared betahistine with placebo; all patients also
had particle repositioning manoeuvres. We judged the quality of evidence overall to be low.
The studies varied considerably in terms of types of participants, their diagnoses, the dose of betahistine and the length of time the
drug was taken for, the study methods and the way any improvement in vertigo symptoms was measured.
Key results
When all studies are taken together, the proportion of patients reporting a reduction of their vertigo symptoms was significantly higher
in the betahistine group than in the placebo group. However, there was significant variability in the results of the studies so this result
should be treated with caution.
The proportion of patients reporting side effects of the medication was similar in both groups: 16% in the betahistine groups and 15%
in the placebo groups. Overall, 16% of patients of both groups withdrew from the studies.
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There was insufficient information about the effect of betahistine on objective tests of inner ear balance organ function. There was no
information on the effect of betahistine on overall quality of life or falls.
Quality of the evidence
We judged the quality of evidence from the included studies to be low, meaning our estimates of the effects of betahistine could turn
out to be inaccurate. The evidence is up to date to September 2015.
Conclusion
Low quality evidence suggests that patients suffering from vertigo from different causes may have some benefit from betahistine in terms
of reduction in vertigo symptoms. Betahistine is generally well tolerated. Future research into the management of vertigo symptoms
needs to use more rigorous methodology and include outcomes that matter to patients and their families.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Betahistine versus placebo for symptoms of vertigo
Patient or population: pat ients with symptoms of vert igo
Setting: outpat ient clinics
Intervention: betahist ine
Comparison: placebo
Time frame: up to 3 months
Outcomes Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality of the evidence
(GRADE)
What happens
Without betahistine With betahistine Difference
Benefits
Proport ion of pat ients
with improvement ac-
cording to global judge-
ment of pat ient sub-
grouped by diagnosis
of part icipants: 606
(11 RCTs)
RR 1.30
(1.05 to 1.60)
Moderate ⊕⊕©©
LOW 123
If 100 pat ients with ver-
t igo are treated with
betahist ine, 60 will im-
prove. This is 14 more
than would have im-
proved if a sham
medicine had been
taken instead of betahis-
t ine
46.2% 60.1%
(48.5 to 73.9)
13.9% more
(2.3 more to 27.7 more)
Harms
Proport ion of pat ients
with adverse ef fects
of part icipants: 819
(12 RCTs)
RR 1.03
(0.76 to 1.40)
Moderate ⊕⊕©©
LOW 24
If 100 pat ients with ver-
t igo are treated with
betahist ine, 16 will ex-
perience adverse ef -
fects. This is 1 more
than would have had
sim ilar symptoms if
a sham medicine had
been taken instead of
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betahist ine
15.2% 15.7%
(11.6 to 21.3)
0.5% more
(3.6 fewer to 6.1 more)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Although stat ist ical heterogeneity (I2 stat ist ic) was 64%, the direct ion of ef fects was consistent.
2Most evidence was f rom studies with serious methodological lim itat ions (unclear sequence generat ion, allocat ion conceal-
ment and blinding).
3Non-validated outcome measures were used to measure improvement.
4Conf idence intervals were wide and crossed thresholds of important benef its and harms.
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B A C K G R O U N D
Description of the condition
Dizziness is a term that is commonly used by patients to describe
various sensations of lightheadedness, imbalance, illusory feelings
of movement or disorientation. Unsurprisingly, perhaps, given its
lack of specificity, the experience of dizziness is common. Four per
cent of all patients registered with a GP in the UK suffer persistent
symptoms of dizziness and at least 3% are severely incapacitated
by their symptoms (Nazareth 1999).
Vertigo is a specific subtype of dizziness. It is defined by the Bárány
Society (the international balance disorders association) as “the
sensation of self-motion when no self-motion is occurring or the
sensation of distorted self-motion during an otherwise normal
headmovement” (Bisdorff 2009). It may be a sensation of rotation
(’spinning vertigo’), or may be a different sensation of self motion
(’non-spinning vertigo’). It is commonly, although not exclusively,
caused by disease of the inner ear and can in this context be referred
to as ’vestibular vertigo’.
In a large German epidemiological population-based study, the
lifetime prevalence of vestibular vertigo was estimated at 7.4%
(Neuhauser 2005). The same study found that the lifetime preva-
lence of vestibular vertigo requiring a medical consultation was
5.8%. Estimates of the prevalence of significant vertigo impacting
on daily life range from 3% to 10% (Murdin 2015).
The pattern of symptomsof vertigo is variable. In some cases symp-
toms may be mild or there may be a single short-lived episode.
Frequently, however, symptoms become prolonged or individuals
become prone to recurrent attacks. The lifetime prevalence for re-
current attacks of vestibular vertigo is 6.5% (Neuhauser 2005). A
Scottish study estimated that 21% of the population had experi-
enced vertigo and 16% of these found the symptoms moderately
or severely disruptive (Hannaford 2005). Importantly, vertigo in-
creases the risk of falls, which in particular is becoming a major
public health problem in the elderly.
Vertigo is a subjective experience. Its measurement is therefore
dependent on the account of the individual experiencing it. There
are some validated and well recognised instruments for assessing
vertigo, for example the Dizziness Handicap Inventory (Jacobson
1990).
Vertigo has many causes including vestibular disorders such as
Ménière’s disease, vestibular neuritis, benign paroxysmal posi-
tional vertigo and migraine, each of which can be diagnosed by
standardised criteria. Vestibular migraine is diagnosed according
to criteria published jointly by the International Headache So-
ciety and the Bárány Society (Lempert 2012). Benign paroxys-
mal positional vertigo is diagnosed according to clinical criteria,
as is vestibular neuritis (Strupp 2013). The Bárány Society and
international collaborating organisations have recently published
consensus clinical criteria for Ménière’s disease (Lopez-Escamez
2015), taking forward the previouslywidely usedAmerican criteria
(AAO-HNS 1995). Other causes of vertigo include neurological
disorders affecting the central vestibular pathways (for example,
some kinds of cerebellar stroke, or inflammatory or demyelinat-
ing pathologies) (Karatas 2010). Psychological disorders and pri-
mary cardiological disorders can also cause a sensation of vertigo
(Newman-Toker 2008; Wiltink 2009). It is therefore important
to assess patients presenting with vertigo very carefully to identify
the underlying diagnosis. However, symptomatic management of
vertigo may be required before a definitive cause can be identified.
Description of the intervention
Betahistine is a drug treatment, available only in oral form, usu-
ally taken in doses from 24 mg to 48 mg daily. It is excreted via
the urinary system. It is also known as betahistine dihydrochlo-
ride and has a number of different proprietary names, including
Serc, Betaserc and Hiserk. It has been used in some countries for
many years as a treatment forMénière’s disease or syndrome, where
it has been thought to be especially effective for the symptoms
of vestibular vertigo. This widely held view was challenged by a
Cochrane review that found no evidence of benefit in Ménière’s
disease or syndrome (James 2001). However, it has also been used
more broadly for the treatment of vestibular vertigo. In a study of
medical practice in a variety of settings across 13 countries world-
wide betahistine was the most common drug prescribed, being is-
sued in two-thirds of cases of vertigo. It was also themost common
drug prescribed across every diagnostic group (Ménière’s, benign
paroxysmal positional vertigo, peripheral vestibular vertigo and
’other’ vertigo) (Agus 2013). A German study set in primary care
found that betahistine was prescribed in 6.6% of consultations
for dizziness, and was most likely to be prescribed in ’unspecified
dizziness’, vestibular neuritis and benign paroxysmal positional
vertigo (Kruschinski 2008).
The main adverse effects of betahistine relate to upper gastroin-
testinal tract symptoms; in general it is believed to be well toler-
ated.
How the intervention might work
Betahistine could act at either a peripheral (inner ear labyrinth)
or central nervous sytem level, with current data favouring a pre-
dominantly peripheral mode of action.
Despite widespread use, the pharmacology of betahistine remains
incompletely understood. Betahistine hydrochloride is a weak his-
tamine H1 agonist and a strong H3 antagonist with virtually no
H2 histamine receptor activity. Betahistine may act on the inner
ear fluid mechanics by improving circulation in the cochlear stria
vascularis (Ihler 2012; Martinez 1972), via an action on the pre-
capillary sphincter with an associated reduction in excessive en-
dolymphatic pressure, improving the function of vestibular hair
cells.
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Betahistine could also have effects on symptoms of vertigo via cen-
tral nervous system activity. Betahistine can cross the blood-brain
barrier: the cell bodies of histamine-containing neurons project
throughout the brain, including the ventromedial hypothalamic
nucleus, the thalamus and the cerebral cortex, and betahistine has
measurable effects on regional cerebral blood flow (Barak 2008).
Data from a single double-blind, placebo-controlled clinical study
suggest significant effects of betahistine on some cognitive func-
tion tests (Pathy 1977). Another possible mechanism of action of
betahistine is via inhibition of activity within the vestibular nuclei
(Timmerman 1994).
Why it is important to do this review
Vertigo is a common symptom that has significant impact on the
health and wellbeing of sufferers both at an individual and a pop-
ulation level. There are evidence-based treatments for common
conditions that cause symptoms of vertigo (e.g. particle reposition-
ing manoeuvres for benign paroxysmal positional vertigo (Hilton
2014;Hunt 2012); drug treatments formigraine (Linde 2004); re-
habilitation for unilateral vestibular disorders like vestibular neu-
ritis (McDonnell 2015)), and the first step in evaluating patients
with this symptom should always be a proper assessment with a
view to making a clear diagnosis to guide evidence-based manage-
ment. However, there remains a need to evaluate other therapies
for vertigo. This is because these treatments may be contraindi-
cated in some patients and others may fail to respond or have
ongoing symptoms. Importantly, many patients with vertigo do
not meet clear-cut diagnostic criteria for a defined condition so
disease-specific treatments cannot always be offered. In these cases
betahistine is often prescribed in clinical practice.
Betahistine is a widely used treatment for Ménière’s disease or syn-
drome. A Cochrane review showed that there is insufficient good
evidence of an effect (James 2001). The authors suggested, how-
ever, that due to difficulties with adherence to the strict diagnostic
criteria for Ménière’s syndrome, a true positive effect of betahis-
tine in patients with less well-defined symptoms may have been
missed.
O B J E C T I V E S
To assess the effects of betahistine in patients with symptoms of
vertigo from different causes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials. We planned to include cross-over
trials if the results from before the cross-over were extractable, to
avoid the potential for carry-over effects.
Types of participants
Patients of any age with vertigo in community or other set-
tings were eligible. Where patients were diagnosed with a specific
vestibular condition, we noted the diagnostic criteria.We excluded
those who had specific diagnoses of non-neurotological causes for
vertigo (such as anxiety disorders or cardiac disease). We included
all categories of neurotological diagnosis (including, for example,
central neurological conditions and vestibular schwannoma).
Types of interventions
We considered any trial of betahistine versus placebo. Planned
comparisons were:
• betahistine versus placebo;
• betahistine with an additional intervention versus placebo
with an identical additional intervention.
We included all dose regimes and all formulations (e.g. slow-release
preparations).We did not include comparisons with other drugs as
their effects on vertigohave not been formally assessed.Concurrent
use of other medication for non-neurotological conditions was
acceptable if used equally in each group. Where an additional
intervention was also used equally in both groups, we analysed
this as a separate comparison.
Types of outcome measures
We examined outcomes as short-term (three months or under)
and long-term (over three months).
The outcomemeasures belowwere not used as a basis for including
or excluding studies.
Primary outcomes
• Proportion of patients with reduction in vertigo symptoms
(considering together the intensity, frequency and duration those
symptoms).
• Proportion of patients with adverse effects. Betahistine is
thought to cause upper gastrointestinal adverse effects and we
recorded these separately.
Secondary outcomes
• Proportion of participants withdrawing (dropping out)
from the study due to all causes.
• Generic quality of life (we assessed disease-specific quality
of life scales as part of the primary outcome).
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• Vestibular function as tested with objective vestibular
function tests: caloric tests, rotation tests, posturography and
vestibular evoked myogenic potentials.
• Proportion of participants with falls, as a real-life indicator
of overall functional balance.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 21 September 2015.
Electronic searches
The Information Specialist searched:
• the Cochrane ENT Trials Register (searched 21 September
2015);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2015, Issue 8);
• PubMed (1946 to 21 September 2015);
• Ovid EMBASE (1974 to 21 September 2015);
• Ovid CAB Abstracts (1910 to 21 September 2015);
• EBSCO CINAHL (1982 to 21 September 2015);
• Ovid AMED (1985 to 21 September 2015);
• LILACS, lilacs.bvsalud.org (searched 21 September 2015);
• KoreaMed (searched via Google Scholar 21 September
2015;
• IndMed, www.indmed.nic.in (searched 21 September
2015);
• PakMediNet, www.pakmedinet.com (searched 21
September 2015);
• Web of Knowledge, Web of Science (1945 to 21 September
2015);
• CNKI, www.cnki.com.cn (searched via Google Scholar 21
September 2015);
• ClinicalTrials.gov (searched via the Cochrane Register of
Studies 21 September 2015);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp (searched
21 September 2015);
• ISRCTN, www.isrctn.com (searched 21 September 2015);
• Google Scholar, scholar.google.co.uk (searched 21
September 2015);
• Google, www.google.com (searched 21 September 2015).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochrane Handbook for Systematic Reviews of
InterventionsVersion 5.1.0, Box 6.4.b. (Handbook 2011)). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, TRIPdatabase,
The Cochrane Library and Google to retrieve existing systematic
reviews relevant to this systematic review, so that we could scan
their reference lists for additional trials.
Data collection and analysis
Selection of studies
Two authors (LM and KH) independently scanned the initial
search results to identify trials that appeared to meet the inclusion
criteria. We used abstract review to eliminate any trials that were
clearly ineligible. If either author identified a paper as potentially
suitable, we reviewed the full text of the article. We resolved dis-
agreements by discussion or with the input of the third author
(AS).
Data extraction and management
Two authors (LM and KH) extracted data independently and syn-
thesised the results. We used standardised data entry forms. There
was no blinding of journal, author names or affiliations. With re-
gard to subgroup analysis, we extracted data on underlying diag-
nosis if applicable, along with treatment protocol (dose and dura-
tion of drug).
For each study, we extracted information on study design, dura-
tion, randomisation, concealment, number of participants, setting
of study, diagnostic criteria and exclusion criteria, age and sex dis-
tribution of participants, country of recruitment, co-morbidity,
date of study, number of intervention groups, betahistine dose and
duration, outcomes measured and definition of outcomes, miss-
ing data and final sample size, data on intensity, frequency and
duration of vertigo, and data from other vertigo scales.
For the outcome proportion of patients with an improvement in
symptoms, a variety of (non-validated) scales with different num-
bers of ordinal points were reported in the studies. Two different
review authors independently dichotomised these into ’improved’
or ’not improved’ whenever possible.
When the required data were not available in the published ac-
counts, we contacted the principal investigator to request the data.
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Assessment of risk of bias in included studies
LM and KH undertook assessment of the risk of bias of the in-
cluded trials independently, with the following taken into consid-
eration, as guided by theCochrane Handbook for Systematic Reviews
of Interventions (Handbook 2011):
• sequence generation;
• allocation concealment;
• blinding;
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We used the Cochrane ’Risk of bias’ tool in RevMan 5 (RevMan
2014), which involves describing each of these domains as reported
in the trial and then assigning a judgement about the adequacy of
each entry: ’low’, ’high’ or ’unclear’ risk of bias.
We resolved differences of opinion by discussion in the first in-
stance, with input from the third author (AS) if necessary.
Measures of treatment effect
The primary outcome measure of this review was the proportion
of individuals with benefit from the drug, which is a dichotomous
measure.
For binary (dichotomous) data we calculated the risk ratio (RR).
For intervention effect measures with continuous data we planned
to calculate the difference in means (mean difference, MD) be-
tween the groups, provided that different studies used the same
scale of measurement. We planned to calculate the standardised
mean difference (SMD) if different scales were used.
For studies with ordinal data we checked, where possible, to see
if the scale had been validated. Depending on the number points
in these scales (and how the data were reported), we either di-
chotomised these or analysed them as continuous outcomes.
Unit of analysis issues
Cluster-randomised trials
Cluster-randomised trials allocate groups instead of individuals.
The participants in each group may be related in some way, there-
fore this needs to be taken into account in the analysis, otherwise
there is a unit of analysis error, which would produce an artificially
small P value and a risk of false positive results. We planned to
analyse these according to guidance in theCochrane Handbook for
Systematic Reviews of Interventions (Handbook 2011). However,
we identified no cluster-randomised trials.
Cross-over trials
Cross-over trials may have a carry-over effect.We have included all
patients with vertigo, some of which may resolve quite quickly. In
view of this, and the chronic and episodic nature of the condition
of interest (vertigo), we used data from cross-over trials only if data
from before the cross-over could be obtained.
Multi-arm studies
Where we found studies with more than two groups (e.g. two or
more active treatments being tested against placebo), we estab-
lished which of the comparisons were relevant to the systematic
review and relevant to each of the meta-analyses that we imple-
mented. Where the study design used independent groups, we
treated the study as an independent comparison.
Repeated observations on participants
In longer studies, results may be recorded at more than one time
interval. In order to avoid a unit of analysis error when combining
these results in a single meta-analysis (and therefore counting the
same participants in more than one comparison), we would have
defined different outcomes, based on different periods of follow-
up, performing separate analyses.
Dealing with missing data
We did not plan or implement any statistical strategies to deal
withmissing data, except for imputations to estimatemissing stan-
dard deviations according to the methods recommended in Sec-
tion 7.7.3 of the Cochrane Handbook for Systematic Reviews of In-
terventions (Handbook 2011). We conducted available case anal-
ysis.
Assessment of heterogeneity
We assessed studies for clinical, statistical and methodological het-
erogeneity.
We assessed heterogeneity by inspection of the point estimates and
confidence intervals on the forest plots.We assessed the variation in
treatment effects by means of the Cochrane test for heterogeneity
and quantified it using the I2 statistic.
An approximate guide to interpretation provided in the Cochrane
Handbook for Systematic Reviews of Interventions is as follows (
Handbook 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
We also used the Chi2 test, using the indicator that where Chi2
was greater than the degrees of freedom, heterogeneity was likely
to be present. We considered heterogeneity statistically significant
if the P value was < 0.1.
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Assessment of reporting biases
Reporting bias can be assessed as between-study publication bias or
within-study reporting bias.
Between-study publication bias
Where there was a sufficient number of trials (more than 10)
in any meta-analysis, we assessed publication bias according to
the recommendations on testing for funnel plot asymmetry as
described in Section 10.4 of the Cochrane Handbook for Systematic
Reviews of Interventions (Egger 1997; Handbook 2011).
Within-study reported bias
Weplanned to assess within-study reporting bias by comparing the
outcomes reported in the published report against the outcomes
reported in the study protocol, whenever this could be obtained. If
a protocol could not be obtained, then we compared the outcomes
listed in the methods section with those reported in the results.
Data synthesis
We planned to analyse all participants according to the group
randomised in the studies. If the data were compatible and of
sufficient quality we planned to combine them to give summary
measures of effect. If sufficient data were available for different
conditions (e.g. uncompensated vestibular disease), we planned
to undertake subgroup analysis. As stated above, all conditions
causing vestibular vertigowere to be included (includingMénière’s
disease), but at the subgroup analysis stage we did not plan to
duplicate work already carried out onMénière’s disease since there
is already a Cochrane review on this specific topic (James 2001).
Subgroup analysis and investigation of heterogeneity
We analysed subgroups by participant factors (diagnosis) and by
intervention factors (dose of betahistine) to examine reasons for
heterogeneity.
Sensitivity analysis
We planned to conduct a sensitivity analysis by comparing the
effect of the inclusion and exclusion of studies based on eligibility
criteria or data analysis methods where required.
GRADE and ’Summary of findings’ table
We used the GRADE approach to rate the overall quality of evi-
dence. The quality of evidence reflects the extent to which we are
confident that an estimate of effect is correct and we applied this in
the interpretation of results. There are four possible ratings: high,
moderate, low and very low. A rating of high quality of evidence
implies that we are confident in our estimate of effect and that
further research is very unlikely to change our confidence in the
estimate of effect. A rating of very low quality implies that any
estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We included a ’Summary of findings’ table, constructed ac-
cording to the recommendations described in Chapter 10 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011). We included the following outcomes in the
’Summary of findings’ table:
• proportion of patients with improvement according to
global judgement of patient subgrouped by diagnosis;
• proportion of patients with adverse effects.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The electronic database search on 21 September 2015 identified
809 records. We identified an additional 10 records from hand-
searching, contactingmanufacturers and experts, and from the ref-
erence lists of relevant studies. We were provided with five further
unpublished studies for analysis. After removal of duplicates we
were left with 445 records. We identified 32 potentially eligible
studies and excluded 15 for reasons including having a cross-over
design with the data from before cross-over not extractable, lack
of adequate randomisation and ineligible participants. Seventeen
studies met the inclusion criteria. The results of the search are
shown in Figure 1 as a flow chart. The excluded studies are tabu-
lated in the Characteristics of excluded studies table. There are no
studies awaiting assessment and two studies are ongoing.
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Figure 1. Process for sifting search results and selecting studies for inclusion.
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Included studies
We included 17 studies and these are summarised in the
Characteristics of included studiestable.
Only Guneri 2012 explicitly reported no financial conflict of in-
terest. Six studies all acknowledge an association with the man-
ufacturers of betahistine (Conraux 1988; Fischer 1985; Legent
1988; Mira 2003; Oosterveld 1989; Otto 2008), and five were
unpublished industry studies (Duphar 77054 1983; Duphar
H10800580M 1984; Duphar H10802786F/M 1989; Duphar
H10803592F 1997; Duphar H108906NL 1990).
Design
Most studies used a prospective, parallel-group comparison design
(Conraux 1988; Duphar 77054 1983; Duphar H10800580M
1984; Duphar H10802786F/M 1989; Duphar H10803592F
1997; Duphar H108906NL 1990; Fischer 1985; Guneri 2012;
Legent 1988;Mira 2003; Okamoto 1968; Otto 2008; Ricci 1987;
Salami 1984). Three studies used a cross-over design, from which
data were extractable prior to cross-over (Burkin 1967; Canty
1981; Oosterveld 1989). In Guneri 2012, betahistine was com-
pared to placebo for the treatment of benign paroxysmal positional
vertigo (BPPV) in addition to usual care (the Epley particle repo-
sitioning manoeuvre). All studies were double-blinded.
Sample sizes
Sample size ranged from 10 (Ricci 1987) to 144 (Mira 2003). A
total of 567 patients had results reported across the 12 published
studies, and there were results for an additional 458 patients from
the five unpublished studies (1025 patients in total).
Setting
The majority of studies were single-centre and appeared to take
place in specialist centres.Mira 2003,Oosterveld 1989 and Legent
1988 were multicentre studies. Studies took place in the USA
(Burkin 1967), the UK (Canty 1981), France (Conraux 1988;
Legent 1988), the Netherlands (Fischer 1985; Oosterveld 1989),
Italy (Mira 2003; Ricci 1987; Salami 1984), Turkey (Guneri
2012), Japan (Okamoto 1968), and Germany (Otto 2008). Of
the unpublished studies, there were two multicentre studies from
France (Duphar H10802786F/M 1989; Duphar H10803592F
1997), and one single-centre study each from the UK (Duphar
77054 1983), France (Duphar H10800580M 1984), and the
Netherlands (Duphar H108906NL 1990).
Participants
Five studies included patients who were designated by the study
authors as having clinically defined Ménière’s disease or syndrome
(Burkin 1967; Mira 2003; Okamoto 1968; Ricci 1987; Salami
1984). In only one of these were the AAO-HNS 1995 diagnostic
criteria cited (Mira 2003), with participants having probable or
possible Ménière’s according to the study authors.
Three studies included patients with episodic vertigo (Canty 1981;
Fischer 1985; Oosterveld 1989), and one included those with
episodic vertigo “with or without cochlear symptoms suggestive
of Meniere’s disease” (Legent 1988). Canty 1981 specified that
symptoms must have a presumed peripheral origin and to have
lasted at least 12months. Two studies includedpatientswithBPPV
defined by a positive Dix-Hallpike positioning test (Guneri 2012;
Mira 2003). One study included patients with chronic vertigo
(Conraux 1988), defined as at least six crises over the last two
months and symptomduration of at least threemonths.One study
included patients with “vertebrobasilar ischaemia”, defined in this
study as vertigo with at least two of impaired hearing, impaired
vision, tinnitus or headache and “typical abnormalities” on test,
which were not specified (Otto 2008).
Duphar 77054 1983,DupharH10802786F/M1989 andDuphar
H10803592F 1997 included patients with Ménière’s disease or
episodic vertigo with cochlear symptoms, but with no strict
diagnostic criteria and with other diagnoses included. Duphar
H108906NL 1990 included patients with various diagnoses in-
cluding a majority with BPPV and small numbers with other
causes of episodic vertigo. Duphar H10800580M 1984 included
patients labelled as having “central signs” with short-lived episodes
of vertigo, this list including changes in handwriting, spontaneous
or induced/gaze evokednystagmus, nystagmus on cervical or verte-
brobasilar privation test and unilateral or bilateral hypo- or hyper-
excitability of vestibular function (Duphar H10803592F 1997).
Burkin 1967 did not report exclusion criteria. Canty 1981, Fischer
1985, Guneri 2012, Legent 1988, Mira 2003, Okamoto 1968,
Oosterveld 1989, Otto 2008, Salami 1984 and Ricci 1987 did re-
port exclusion criteria. Patients on other relevant vestibular med-
ication were excluded by Conraux 1988, Fischer 1985, Guneri
2012, Otto 2008 and Salami 1984. No published studies ex-
cluded those who had previously been on betahistine, but two
unpublished studies did (Duphar H10803592F 1997; Duphar
H108906NL 1990).
All studies were of adults, but one study reported that the youngest
participants were teenagers (Okamoto 1968). The oldest partici-
pants in the studies were in the eighth decade (Guneri 2012; Otto
2008). Two studies did not report age and gender data for partic-
ipants (Conraux 1988; Legent 1988). Some studies had an upper
age limit for inclusion (Fischer 1985;Mira 2003; Oosterveld 1989
used 65 years as the upper limit; Duphar H10800580M 1984;
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Duphar H108906NL 1990; Duphar 77054 1983 used an upper
limit of 70, Guneri 2012 used an upper limit of 79 years). All
studies where gender was reported had mixed male and female
participants.
Interventions
All studies compared betahistine against placebo.
Doses of betahistine ranged from daily totals of 16 mg (Burkin
1967), 24 mg (Ricci 1987; Salami 1984), 32 mg (Canty 1981;
Mira 2003), 36 mg (Okamoto 1968; Otto 2008), or 48 mg
(Fischer 1985; Legent 1988; Oosterveld 1989). The unpublished
studies used totals of 36 mg (Duphar 77054 1983), or 48 mg
(Duphar H10800580M 1984; Duphar H10802786F/M 1989;
Duphar H10803592F 1997; Duphar H108906NL 1990). Some
studies used variable doses (Conraux 1988). Duration of treat-
ment available for analysis in this review was a fixed interval of
two weeks (Burkin 1967; Guneri 2012; Okamoto 1968), one
month (Duphar H10803592F 1997), five weeks (Oosterveld
1989), sixweeks (Salami 1984), twomonths (Canty 1981;Duphar
H108906NL 1990), and three months (Conraux 1988; Fischer
1985; Legent 1988; Mira 2003, Duphar 77054 1983; Duphar
H10800580M 1984; Duphar H10802786F/M 1989). Study du-
ration was three months or less in all cases except Ricci 1987,
where duration of therapy was variable (using a protocol of 10
times mean duration of interval between attacks for each patient
to determine treatment length). In this small study of 10 patients
therapy was for a mean of 10.4 months in the betahistine group
and 7.0 months in the placebo group.
Guneri 2012 compared betahistine (48 mg daily) with placebo in
patients with BPPV who had also received particle repositioning
manoeuvres as an additional intervention.
Assessment of intervention integrity in the form of compliance
was variably reported. Compliance checks were not reported in
most studies (Burkin 1967; Conraux 1988; Duphar 77054 1983;
Duphar H10800580M 1984; Duphar H10802786F/M 1989;
Guneri 2012; Legent 1988;Mira 2003; Ricci 1987; Salami 1984).
Four studiesmade direct or indirect reference to compliance checks
either by checking tablet containers or by labelling some patients
as non-compliant (Canty 1981; Fischer 1985; Okamoto 1968;
Oosterveld 1989). Three studies reported that compliance was
explicitly checked by direct questioning and container checks (
Duphar H10803592F 1997; Duphar H108906NL 1990; Otto
2008).
Outcomes
Proportion of patients with reduction in vertigo symptoms
(considering together the intensity, frequency and duration
those symptoms)
Ten studies collected data on patient global satisfaction with treat-
ment using various different ordinal scales, which we interpreted
as overall improvement where the rating was positive (Conraux
1988; Duphar H108906NL 1990; Duphar 77054 1983; Duphar
H10800580M 1984; Duphar H10803592F 1997; Fischer 1985;
Legent 1988; Mira 2003; Oosterveld 1989; Otto 2008). In ad-
dition, four studies reported vertigo scores in a way that enabled
us to quantify the proportion of patients who experienced overall
improvement in vertigo symptoms, using either dichotomous or
ordinal scales of overall benefit in terms of vertigo (Burkin 1967;
Canty 1981; Conraux 1988; Okamoto 1968). These scales were
not described as validated.
Seven studies collected parallel data on the investigator global im-
pression of treatment (Fischer 1985; Duphar H108906NL 1990;
Duphar 77054 1983; Duphar H10802786F/M 1989; Duphar
H10800580M 1984; Duphar H10803592F 1997; Mira 2003).
However, in this review we have focused on the more clinically
relevant outcome of patient-reported improvement.
Guneri 2012 used published validated scales (Dizziness Handi-
cap Inventory (Jacobson 1990), Vestibular Disorders Activities of
Daily Living Scale (Cohen 2000), Vertigo SymptomScale (Yardley
1998), and European Evaluation of Vertigo Scale (Megnigbeto
2001). Mira 2003 also used the Dizziness Handicap Inventory
and some other scales whose validation references could not be
obtained (Dizziness Assessment Rating Scale, GISFaV).
Ricci 1987 reported in narrative terms the small number of pa-
tients in that study. Burkin 1967 used a “dizzy or not” dichoto-
mous outcome.
Intensity of vertigo
Okamoto 1968 used a three-point, author-defined ordinal scale
to measure intensity of vertigo. Similarly, six studies used a four-
point ordinal scale (Canty 1981; Duphar 77054 1983; Duphar
H10803592F 1997; Fischer 1985; Otto 2008; Salami 1984), and
six studies used a five-point ordinal scale (Conraux 1988; Duphar
H10802786F/M 1989; Duphar H10800580M 1984; Duphar
H10803592F 1997; Legent 1988; Oosterveld 1989). In Otto
2008, patients rated a number vertigo symptoms (unsteadiness,
staggering, rotary sensation, tendency to fall, lift sensation, sway-
ing, selfmotion triggered vertigo) and for each individual themean
score across all these symptoms was calculated.
Frequency of vertigo
Six studies reported the frequency of attacks (Duphar
H108906NL 1990; Duphar H10803592F 1997; Fischer
1985; Legent 1988; Mira 2003; Oosterveld 1989). Duphar
H10803592F 1997 reported the total number of attacks through
the 30-day study period. Duphar H10802786F/M 1989 reported
the time since the last attack at study endpoint.
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Duration of vertigo
Two studies also reported duration of vertigo attacks on an author-
defined four-point ordinal scale (Fischer 1985; Oosterveld 1989).
Legent 1988 reported mean duration of attacks per patient in
hours. Mean duration of attacks in seconds was recorded by two
studies (DupharH108906NL 1990;DupharH108906NL 1990).
Salami 1984 reported total duration of attacks.
Proportion of patients with adverse effects
All studies except Guneri 2012 and Ricci 1987 made some com-
ment on tolerability or safety. Duphar H10802786F/M 1989 did
not describe adverse effects directly but measured “tolerance” on
a four-point ordinal scale.
Proportion of participants withdrawing (dropping out) from
the study due to all causes
Withdrawal from study was reported clearly by six studies
(Duphar 77054 1983; Duphar H10800580M 1984; Duphar
H10802786F/M 1989; Duphar H10803592F 1997; Mira 2003;
Salami 1984).
Generic quality of life
No study included a general quality of life measure.
Vestibular function as tested with objective vestibular
function tests
Three studies also reported vestibular function tests (caloric, sta-
bilometry, nystagmography) (Canty 1981; Mira 2003; Salami
1984). Guneri 2012 and Mira 2003 used Dix-Hallpike position-
ing testing to assess resolution of BPPV. Although one study had
a majority of participants with BPPV, Dix-Hallpike test outcomes
are not reported (Duphar H108906NL 1990). Duphar 77054
1983 reported the intention to collect vestibulometric tests as out-
comes, but these were not done at the “discretion of the investi-
gator”.
Proportion of participants with falls
No study reported on falls outcomes.
Excluded studies
See Characteristics of excluded studies for details of the 15 stud-
ies that we excluded. Five studies were of cross-over design, with
data before cross-over not extractable (Frew 1976; Meyer 1985;
Oosterveld 1984; Watanabe 1967; Wilmot 1976). We excluded
six studies as there was no evidence of randomisation (Bertrand
1972; Hommes 1972; Purohit 1988; Singarelli 1979; Verspeelt
1996), or randomisation was inadequate (Elia 1966).We excluded
two as the participants did not meet the criteria for the symp-
tom definition of vertigo according to the review protocol (Redon
2011; Schmidt 1992).
Ongoing studies
Four registered clinical trials were identified through the search.
Two studies were identified as progressing but with data not yet
published. The co-ordinator of these two trials confirmed progress
by personal communication (BEMED; BETAVEST). One regis-
tered clinical trial was a drug company trial of betahistine for post-
vestibular neurotomy patients with Ménière’s disease, which was
closed in 2006 (NCT00160238). Another registered clinical trial
entry (of betahistine for vertigo caused by cerebral infarction in
posterior circulation) reported that the study was terminated early
due to poor recruitment (NCT00474409). We contacted the reg-
istered companies for any results but these have not been received
at the time of writing.
Risk of bias in included studies
Two authors (LM and KH) critically reviewed studies for risk
of bias. We contacted lead study authors for further details of
methodology where required. We also contacted authors for clar-
ification of methodological issues where these were unclear. Prof
Oosterveld replied to our enquiries to say that as the study took
place such a long time ago, the original paperwork for the study is
no longer available for inspection to clarify details or fill in missing
data (Oosterveld 1989). No other responses had been received by
the time of submission.
For sequence generation six studies had a low risk rating and 11
were unclear. For allocation concealment, two had a low risk rating
and 15 were unclear. For blinding, three had a low risk rating,
one had a high risk rating and 14 were unclear. For attrition bias,
four were low risk and 10 were high risk. For reporting bias, nine
were high risk and six low risk. In Canty 1981, some included
participants in both groups had no symptoms at all throughout
the whole trial duration, including the baseline assessment period,
and this was also flagged up as a problem. Risk of bias is presented
graphically in Figure 2 and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
All studies reported that they were randomised. The major-
ity (11 studies) gave no information on how this was achieved
(Burkin 1967; Canty 1981; Conraux 1988; Duphar 77054 1983;
Duphar H10802786F/M 1989; Duphar H108906NL 1990;
Fischer 1985; Guneri 2012; Legent 1988; Oosterveld 1989;
Salami 1984); the risk of bias was unclear. Six studies reported
details of the randomisation methods, which were adequate and
we considered them as at low risk of bias (Duphar H10800580M
1984; Duphar H10803592F 1997; Mira 2003; Okamoto 1968;
Otto 2008; Ricci 1987).
Allocation concealment
Only Mira 2003 and Okamoto 1968 reported details relating to
allocation concealment, with both reporting that the allocation
was done on a different site to the investigating centre. These
studies were at low risk of bias. All the other studies were at unclear
risk of bias.
Blinding
All studies were reported as “double-blind” but most gave no fur-
ther details, so we allocated these studies ratings of unclear risk.
Primary outcome measures were mostly by self report, unsurpris-
ingly, given the subjective nature of vertigo symptoms. Mira 2003
reported that drugs were supplied in identical packages with a
false name, so we awarded it a low risk rating. Guneri 2012 com-
mented on blinding of the trial physician and we also awarded
this study a low risk rating on this basis. Most studies commented
that the placebo tablet was “identical” or “indistinguishable” from
the betahistine preparation, with only two giving no information
(Guneri 2012; Ricci 1987). In Duphar 77054 1983, it is stated
that envelopes were provided to all participants stating allocation,
however returned sealed envelope collection is not reported and
opacity was not stated, therefore we judged this high risk. Like-
wise, Duphar H10803592F 1997 stated “neither patient nor in-
vestigator knew which treatment was being given” and we allo-
cated low risk. Duphar H10802786F/M 1989 described coding
envelopes all being returned unopened, but opacity was not stated
so we rated this as unclear.
Incomplete outcome data
Mira 2003 reported that randomised patients were all accounted
for and there was a low rate of attrition so we rated it low risk.
For Duphar H10800580M 1984, enough information was given
for intention-to-treat (ITT) analysis to be possible and losses were
under 20%. We judged it low risk on this item. Canty 1981 lost
data on five of 32 participants, but reported data on all includ-
ing one of the five who was subsequently found to be ineligible.
However, the dropouts occurred in the second phase of cross-over,
which is not relevant to the data considered for this review, so we
deemed the study low risk.
Seven studies all reported some attrition but did not address
this in the analysis or provide data that we could use to do
so and so we rated them high risk (Duphar 77054 1983;
Duphar H10802786F/M 1989; Duphar H108906NL 1990;
Fischer 1985; Legent 1988; Oosterveld 1989; Otto 2008). For
Duphar H10803592F 1997, information on all the lost partici-
pants was incomplete and we judged it high risk. Four studies did
not give complete data for the group allocation of the lost par-
ticipants (Conraux 1988; Fischer 1985; Legent 1988; Oosterveld
1989). Okamoto 1968 reported that two patients withdrew from
each group, but not due to adverse effects (James 2001).
Salami 1984 reported zero attrition (personal communication re-
ported in James 2001) and so we rated this low risk. Burkin 1967,
Guneri 2012 and Ricci 1987 gave no information on attrition and
we judged them unclear risk on this basis.
Selective reporting
No pre-published protocols were available for inspection to facil-
itate assessment for reporting bias. Conraux 1988 reported raw
data and measures of spread were missing for important variables
that were apparently collected, such as frequency of attacks; we
thus rated it high risk. Guneri 2012 and Ricci 1987 did not report
any information on adverse effects or tolerance and so we rated
themhigh risk.Mira 2003 andOtto 2008 did not present absolute
values or baseline data, only percentage changes in variables, so
we rated them as high risk. Canty 1981 presented vertigo scores
that are not fully described in the methods and we judged this
high risk. Mira 2003 also recruited patients with benign paroxys-
mal positional vertigo but did not report Dix-Hallpike tests as an
outcome. In Duphar H10800580M 1984, there were no data on
neuro-otological findings although these were part of the diagnos-
tic criteria and appear to have been assessed and so we judged this
high risk. We rated the other studies unclear on the basis of the
absence of a pre-published protocol.
Other potential sources of bias
Baseline similarity of groups with respect to clinical disease param-
eters, such as vertigo duration or severity, was not clearly reported
in three studies (Burkin 1967; Conraux 1988; Guneri 2012).
Four studies showed some differences between active and placebo
17Betahistine for symptoms of vertigo (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
groups at baseline, not accounted for in the analysis techniques
(Fischer 1985; Legent 1988; Otto 2008; Ricci 1987). Groups ap-
pear well matched in Okamoto 1968 and all the unpublished
manufacturer trials (Duphar 77054 1983; Duphar H10800580M
1984; Duphar H10802786F/M 1989; Duphar H10803592F
1997; Duphar H108906NL 1990). Most studies did not exclude
participants who had previously taken betahistine.
Effects of interventions
See: Summary of findings for the main comparison Betahistine
versus placebo for symptoms of vertigo
Betahistine versus placebo
Primary outcomes
Proportion of patients with reduction in vertigo symptoms
(considering together the intensity, frequency and duration
of those symptoms)
The proportion of patients who reported overall reduction
in symptoms is given in Analysis 1.1. Twelve studies yielded
analysable data. Although Mira 2003 collected data using the val-
idated Dizziness Handicap Inventory (DHI), the results were re-
ported only as percentage reductions with no baseline absolute
values and missing measures of spread, so no useful data could be
extracted.
The pooled risk ratio (RR) was 1.30 (95% confidence interval
(CI) 1.05 to 1.60; 606 participants; 11 studies, I2 = 64%) in
favour of betahistine. The heterogeneity was not resolved when
we carried out subgroup analyses, first based on clinical diagnostic
(participant) factors (Analysis 1.1), and then based on intervention
factors (Analysis 1.2).
Firstly, in terms of clinical diagnostic (intervention) factors, we
considered whether heterogeneity could be reduced by looking
at the diagnostic groups of benign paroxysmal positional vertigo
(BPPV),Ménière’s disease (by investigator diagnosis) or ’other ver-
tigo’ (Analysis 1.1). These results need to be interpreted with cau-
tion as the diagnosis of Ménière’s disease was investigator-defined
and did not necessarily meet standard criteria.
Subgroups still showed high statistical heterogeneity (Ménière’s: I
2 = 41%; other vertigo: I2 = 68%). The pooled risk ratio for the
Ménière’s subgroup was 1.56 (95% CI 0.92 to 2.65; 139 partici-
pants; three studies), for BPPV it was 1.34 (95% CI 0.85 to 2.10;
63 participants; one study) and for ’other vertigo’ it was 1.24 (95%
CI 0.97 to 1.58; 404 participants; eight studies).
Secondly, in terms of intervention factors, we looked at total daily
betahistine dosage (Analysis 1.2). For doses of betahistine under
48 mg per day, the pooled risk ratio was 2.11 (95% CI 1.03 to
4.30; 292 participants; six studies) in favour of betahistine, with
the caveat that statistical heterogeneity was again high (I2 = 89%).
For higher doses (48 mg or more) the pooled RR was 1.16 (95%
CI 0.92 to 1.48; 314 participants; five studies), also with high
statistical heterogeneity (I2 = 54%). This analysis is illustrated in
Figure 4.
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Figure 4. Forest plot of comparison: 1 Betahistine versus placebo, outcome: 1.2 Proportion of patients with
improvement according to global judgement of patient: subgrouped by drug dose.
We created a funnel plot for this analysis, as more than 10 studies
were included (Figure 5). We noted asymmetry, raising the possi-
bility of publication bias. However, sensitivity analysis by remov-
ing two studies with low numbers of participants and large effect
sizes, Burkin 1967 and Otto 2008, showed no difference in the
overall effect size but reduced the statistical heterogeneity slightly
(RR 1.23, 95% CI 1.04 to 1.45; 562 participants; 10 studies; I2
= 49%) and the funnel plot was then symmetrical.
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Figure 5. Funnel plot of comparison: 1 Betahistine versus placebo, outcome: 1.1 Proportion of patients with
improvement according to global judgement of patient: subgrouped by diagnosis.
We rated the quality of the evidence for this outcome as low (see
Summary of findings for the main comparison).
Proportion of patients with adverse effects
All trials except Ricci 1987 made reference to adverse effects.
Among the other studies, there was marked variation in findings.
The data for number of patients with adverse effects is shown in
Analysis 1.3. The proportion of patients with adverse effects was
70/418 (16%) in the betahistine group and 61/401 in the placebo
group (15%). Pooling the results give a risk ratio of 1.03 (95% CI
0.76 to 1.40; 819 participants; 12 studies).
Betahistine is frequently thought to cause upper gastrointestinal
adverse effects. Six studies reported adverse effects in sufficient
detail to analyse how many individuals reported upper gastroin-
testinal effects (Conraux 1988; Duphar 77054 1983; Duphar
H10803592F 1997; Duphar H108906NL 1990; Mira 2003;
Otto 2008). Studies that reported that no patients in either group
had unwanted effects were not included in this analysis. Pooling
the results for upper gastrointestinal effects gives a risk ratio of
1.38 (95%CI 0.67 to 2.82; 587 participants; six studies) (Analysis
1.4).
The next most common adverse effect reported in these studies
was headache. Of those studies where headache was recorded as
an unwanted effect in either group, the pooled risk ratio was 0.88
(95% CI 0.15 to 5.19; 515 participants; four studies) (Analysis
1.5).
Six studies reported no adverse events in either the placebo
or betahistine groups (Burkin 1967; Canty 1981; Duphar
H10800580M 1984; Fischer 1985; Okamoto 1968; Salami
1984). Legent 1988 reported non-vestibular complaint effects in
91% of both the placebo and the betahistine groups, but it was
unclear how many patients were in each group. Oosterveld 1989
reported adverse effects in detail but this was a cross-over study
and the figures provided pooled both cross-over periods so we did
not include the data in this analysis. In Duphar H10802786F/M
1989, adverse events are reported as “tolerance” and given as “poor”
in 0/21 in the betahistine group and 3/26 in the placebo group,
so we did not include this study in the analysis for this outcome.
Adverse effects reported in the betahistine group included upper
gastrointestinal symptoms, rash, weight gain, nausea, headache,
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dry mouth, diuresis, rash, fatigue, tinnitus and hyperacusis. One
patient in Mira 2003 was recorded as having dysmyelopoiesis
on betahistine. One patient in Duphar H108906NL 1990 had
respiratory distress on betahistine and one patient in Duphar
H10803592F 1997 had an asthma attack on betahistine. No
placebo patients reported these effects.
We rated the quality of the evidence for this outcome as low (see
Summary of findings for the main comparison).
Secondary outcomes
Proportion of participants withdrawing (dropping out) from
the study due to all causes
The proportion of participants who withdrew or were lost to fol-
low-up is recorded in Analysis 1.6. We pooled the data, giving a
risk ratio of 0.96 (95% CI 0.65 to 1.42; 481 participants; eight
studies; I2 = 0%).
There was no significant difference between the betahistine and
placebo groups in any study or in the pooled analysis.
Generic quality of life
There were no studies that reported using a generic health-related
quality of life instrument (e.g. SF-36). The Dizziness Handicap
Inventory (DHI) is a mixture of quality of life and symptom sever-
ity scores, which is considered under symptom-specific measures.
Vestibular function as tested with objective vestibular
function tests
Canty 1981, Salami 1984 and Otto 2008 included some objective
measure of vestibular function.
Canty 1981 reported assessing caloric tests at baseline and after
treatment, stating that the test was abnormal in nine patients be-
fore treatment with “some improvement” in two of these. As these
effects were observed in a cross-over design study and details of
the timing of drugs and tests were not given, we undertook no
further interpretation for this review.
Craniocorpography results and evaluation for nystagmus are re-
ported in Otto 2008. The paper reported a statistically signifi-
cant difference in change in sway on Romberg and Unterberger
tests, with a greater reduction in the betahistine group than in the
placebo group.
Salami 1984 reported that in the betahistine group, in 13 patients
with abnormal tests at baseline 10 patients (77%) had normalisa-
tion after six weeks of treatment. In the placebo group, 14 had ab-
normal tests at the beginning and this was unchanged at six weeks
(0%). We calculate that this gives a P value of 0.006 (Fisher’s exact
test).
There was one study that included patients with benign paroxys-
mal positional vertigo and it did not report Dix-Hallpike tests as
an outcome measure (Mira 2003).
Pooling datawas inappropriate for this outcome given the diversity
of techniques used to measure vestibular function.
Proportion of participants with falls
No studies reported falls as an outcome measure.
Betahistine plus particle repositioning versus placebo
plus particle repositioning
Primary outcomes
Proportion of patients with reduction in vertigo symptoms
(considering together the intensity, frequency and duration
of those symptoms)
Guneri 2012 reported that there was no statistically significant
difference (“P value > 0.05”) in the mean scores between groups
at one week. For the DHI, the authors reported that the placebo
group had amean score 12.15 (95% CI 10.5 to 13.4) at one week,
and the betahistine group had a mean score of 10.42 (95% CI 4.7
to 16.1). On the Vertigo Symptom Scale (VSS) they reported that
the placebo group had mean score of 2.88 (95% CI 2.83 to 2.93)
at one week, and the betahistine group had a mean score of 2.17
(95% CI 2.13 to 2.21).
Secondary outcomes
Proportion of patients with adverse effects
Adverse effects were not reported.
Proportion of participants withdrawing (dropping out) from
the study due to all causes
Withdrawals from the study were not reported.
Generic quality of life
Generic quality of life was not reported (although we note that the
DHI has some symptom-specific quality of life aspects and this
scale is considered above).
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Vestibular function as tested with objective vestibular
function tests
Guneri 2012 found persistently positive Dix-Hallpike tests (indi-
cating no improvement) at one week in 4/26 (16%) with placebo
and 3/24 (13%) with betahistine.
Proportion of participants with falls
Falls were not reported.
D I S C U S S I O N
Summary of main results
The objective of this review was to evaluate the overall efficacy of
betahistine for symptoms of vertigo.
The primary outcome of this reviewwas the proportion of patients
with overall clinical improvement. There was a pooled risk ratio
for overall improvement of 1.30 (95% confidence interval (CI)
1.05 to 1.60) in favour of betahistine. The pooled data should
be interpreted with caution as the tests of statistical heterogeneity
gave high results. The evidence for the outcome “proportion of
patients with reduction in vertigo symptoms” is of low quality
using the GRADE assessment, especially with respect to blinding
and randomisation, which are of huge importance when studying
vertigo as an outcome measure.
The 17 studies in this review had 1025 participants. Of the 17
included studies, five were unpublished studies funded and led by
the manufacturers of betahistine.
The studies took place over a maximum of three months and so
the longer-term effects of betahistine are unknown.
Betahistine was associated with adverse events in 16% of par-
ticipants; this was very similar to the rate in the placebo group
(15%). The rate of upper gastrointestinal symptoms and headache
was similar in the betahistine and placebo groups. There were
two reports of asthma/respiratory distress in the betahistine group
and none in the placebo group. There was one report of dys-
myelopoiesis in the betahistine group and none in the placebo
group. The high rate of unwanted symptoms in the placebo group
was notable. This suggests that patients with vertigo may fre-
quently experience other symptoms as part of their condition.
However, the GRADE assessment for this outcome was also ’low’,
suggesting that the result should be interpreted with caution.
The review did not identify any subgroups that might particu-
larly benefit from betahistine. This might be expected, given the
fact that the studies were heterogeneous in terms of both partic-
ipant diagnoses and also the diagnostic criteria used to identify
subgroupings. Also, the overall effect size is at best a small one,
meaning that numbers in any subgroup analysis are quite possibly
too low to detect any effect. There is one pre-existing Cochrane
review on betahistine for Ménière’s disease or syndrome, which
found no clear evidence of benefit in that group, and our findings
are in keeping with this (James 2001).
The subgroup analysis did not indicate a dose response relation-
ship of betahistine. When examining the effect of dose, there was
evidence of a small effect in the studies using lower doses but not
in the studies using higher doses. There could be a number of
possible explanations for this observation. Firstly, it is possible that
the effect in the low-dose group is a false positive finding. The
GRADE quality of evidence for this outcome is low and the pos-
itive effect may be the result of study bias. Secondly, it is possible
that the difference between the two subgroups is accounted for
by other methodological differences between the studies, such as
participant diagnoses. Thirdly, it is possible that the numbers of
participants in the higher-dose group were inadequate to detect a
small effect. It is important to remember that the absence of an
effect in the higher-dose group in this subgroup analysis does not
necessarily indicate that there genuinely is no effect. None of the
included studies compared different doses of betahistine within
the same protocol.
Overall completeness and applicability of
evidence
The studies included in this review were conducted in clinical
populations that appear to be similar to those who might receive
betahistine in clinical practice, in that the participants all had ver-
tigo with broad diagnostic inclusion criteria. However, they were
all conducted using secondary or tertiary care level populations
where there are more resources tomake diagnoses. Thismeans that
there may be limited applicability to primary care settings where
these resources are absent.
We searched a large number of databases and trial registries so we
are confident that we traced all relevant trials. There is a concern,
however, about potential reporting biases. We have overcome this
as best we can by successfully obtaining unpublished evidence
frommanufacturers, sought by writing tomanufacturers and from
cited references in review papers. Of the 17 studies included, five
were unpublished trials, but the manufacturers could provide us
with data. We also found two registered clinical trials that had
been terminated early due to poor recruitment (NCT00160238;
NCT00474409). We contacted the drug companies sponsoring
these trials, but no information had yet been provided to us at the
time of publication of this review.
Quality of the evidence
Although we found a relatively large number of trials for this
review (17 trials with 1025 participants), the overall quality of the
evidence was low, meaning that further research is likely to have an
22Betahistine for symptoms of vertigo (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
important impact on the interpretation of these results (Summary
of findings for the main comparison).
There were significant methodological limitations in the conduct
and reporting in these studies, particularly in terms of lack of clar-
ity about patient recruitment/diagnostic criteria, choice of out-
comes used (and reported) and very small sample sizes. None of
the included studies used validated questionnaire data that could
be analysed in this review.
None of the studies was of the highestmethodological quality, with
all studies except two rated as ’high risk’ on at least one item of the
’Risk of bias’ assessment. Statistical and clinical heterogeneity were
high and few studies used validated outcomes, which are of critical
importance for a subjective symptom such as vertigo. In addition,
we are unsure about the quality of blinding of participants in the
majority of studies. Although the studies were reported as “double
blind”, few details were supplied on how this was achieved. Since
vertigo is a subjective outcome and is subject to psychological in-
fluences, adequate blinding is crucial in the execution of studies
assessing the effects of interventions. However, with an interven-
tion that is in tablet form, blinding should be straightforward to
achieve.
None of the included studies had a pre-published protocol avail-
able for inspection. However, we note two ongoing or recently
completed studies for which such a protocol is available (BEMED;
BETAVEST).
Potential biases in the review process
Our searches of the electronic databases were comprehensive. Lan-
guage was not a barrier to inclusion and we included papers in
French, Italian, Japanese andDutch. Author roleswere pre-defined
in the review process. Two authors selected studies for inclusion,
extracted data and judged risk of bias independently, with recourse
to the third author for resolution of disagreement or uncertainty.
Two authors independently extracted data to minimise personal
bias, and we considered both clinical and statistical heterogeneity
before carrying out our analysis.
Agreements and disagreements with other
studies or reviews
There are at least three other reviews of betahistine in the treatment
of vertigo (DellaPepa 2006;Nauta 2014;Ramos 2015).DellaPepa
2006 andNauta 2014 both found favourable effects of betahistine,
as we did.
Nauta 2014 is a review and meta-analysis focused on the outcome
“investigator global assessment of benefit”. Nauta found a ben-
eficial effect of betahistine over placebo for both Ménière’s dis-
ease and vestibular vertigo, calculating a pooled odds ratio (OR)
of 2.58 (95% CI 1.67 to 3.99), with sub-analyses conducted for
patients with Ménière’s disease (OR 3.37, 95% CI 2.14 to 5.29)
and for vestibular vertigo (OR 2.23, 95% CI 1.20 to 4.14). Nauta
did not consider risk of bias in underlying studies, nor other out-
comes than investigator global opinion. For our review we chose
to use the patient’s perspective for improvement rather than the
investigator’s perspective.
Della Pepa 2006 is a review and meta-analysis of randomised con-
trolled trials of betahistine against placebo for symptoms of ver-
tigo carried out between 1979 and 2003. This analysis excluded
studies of patients with Ménière’s disease. Of the seven studies
included (Canty 1981; Fischer 1985; Legent 1988; Mira 2003;
Oosterveld 1989; Oosterveld 1984; Singarelli 1979), some are ex-
cluded from our review for methodological reasons (Oosterveld
1984; Singarelli 1979). The authors calculated an odds ratio in
favour of betahistine of 3.52 (95% CI 2.40 to 3.51).
Ramos 2015 performed a narrative review without meta-analysis
and concluded that betahistine is safe and effective.
Since we completed the search and analyses another relevant study
has been published, which examines the effect of betahistine on
vertigo in patients with Ménière’s disease (Adrion 2016). This
trial is noted in the ongoing studies section above (BEMED). The
authors conclusions are that the incidence of attacks related to
Ménière’s disease did not differ between the three treatment groups
and that treatment was well tolerated with no unexpected safety
findings. This study will be included when this review is updated.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence that is largely of low quality suggests that in patients
suffering from vertigo from different neuro-otological causes there
may be a positive effect of betahistine in terms of reduction in
vertigo symptoms. The same evidence suggests that betahistine
is generally well tolerated with a similar risk of adverse events to
placebo treatments.
Why might betahistine have an effect on such a heterogeneous
group of patients with vertigo from so many different and con-
trasting conditions?Onewould have to hypothesise that the symp-
tom of vertigo in a significant number of these individuals might
have a common pharmacological basis located presumably in the
labyrinth or brain or the connections thereof, and that betahistine
is able to influence this favourably. However, the symptom of ver-
tigo has many possible causes. The findings of this review do not
negate the need for a proper clinical assessment of patients with the
symptom of vertigo with the goal of making a diagnosis. There are
many other evidence-based treatments for particular conditions
that cause vertigo, which should be offered where appropriate.
This review and analysis were set up to answer the question, “is
betahistine of overall benefit to patients with symptoms of vertigo?
”. Patients and their doctors will want to know whether the overall
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benefit from betahistine, if there is one, is large or small, and
whether it is worth the risk of developing adverse effects. The
review was not set up to analyse the size of any benefit since we
examined only whether the patient judged that there was overall
improvement of any degree, which makes it difficult for us to
comment on how large the effect was. What we can say of the
outcome measured was that patients overall felt there was benefit
to them of taking the drug, taking all the relevant factors into
consideration. We can also say that the number of patients who
identified such a benefit over and above the placebo effect was
small.
Implications for research
Future research into the effectiveness of betahistine in patientswith
vertigo should use rigorous methodology. There is a requirement
for the development of and adherence to standardised diagnostic
criteria for the selection of patients.
We also recommend the development of validated, patient-centred
outcome measures for research in the field of balance disorders. At
the time of the publication of this review, core outcome measures
for dizziness had not been identified.
Randomisation and blinding should be of the highest quality,
given the subjective nature of vertigo and the strong likelihood
of a placebo response. Future studies should be conducted and
reported according to the CONSORT statement. Recruitment of
adequate numbers has clearly been problematic for researchers and
this should be considered in future trial designs, such as by using
a multi-centred trial design.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Burkin 1967
Methods Allocation: randomised, but no further details given
Design: cross-over with data extractable before cross-over occurred
Participants Number: 22 analysed
Age: 37 to 58
Gender: 50% female
Setting: ENT department
Eligibility criteria: investigator’s clinical diagnosis of Ménière’s disease
Exclusion criteria: not specified
Baseline characteristics: not given
Interventions Betahistine 4 mg 4 times a day versus placebo over 2 weeks before cross-over
Intervention group:
n = 11
Comparator group:
n = 11
Use of additional interventions: none
Outcomes Primary outcome: dizziness - present or absent dichotomy
Secondary outcomes: adverse events
Funding sources Not specified
Declarations of interest Not given
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”; no further information
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind; “neither patient nor inves-
tigator knew which group” but no further
details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind
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Burkin 1967 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Participants lost to follow-up: not specified
Selective reporting (reporting bias) Low risk Appropriate outcomes
Other bias Unclear risk -
Canty 1981
Methods Allocation: no information
Design: cross-over with data extractable before cross-over occurred
Participants Number: 32 randomised
Age: 26 to 62
Gender: 29 M and 13 F
Setting: not specified
Eligibility criteria: episodic vertigo of peripheral origin for at least a year
Exclusion criteria: central vertigo, Ménière’s, asthma, peptic ulcer
Baseline characteristics: no details
Interventions Betahistine 32 mg for 8 weeks versus placebo
Intervention group:
n = 15
Comparator group:
n = 17
Use of additional interventions: none
Outcomes Primary outcome: vertigo scores (4-point ordinal scale)
Secondary outcomes: caloric and oculomotor tests, adverse events
Funding sources Not given
Declarations of interest Not specified
Notes Some participants in both groups had no symptoms throughout the trial duration
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”; no further information
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”, but no further informa-
tion
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Canty 1981 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”, but no further informa-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants lost to follow-up: 0 in first
treatment phase (before cross-over)
Selective reporting (reporting bias) High risk Outcomemeasures unclear. Also using first
arm of cross-over only. Adverse events only
reported if “considered to represent adverse
reactions to the study drug” without ex-
plicit criteria
Other bias High risk Some patients asymptomatic throughout
entire trial period
Conraux 1988
Methods Allocation: not reported
Design: prospective, parallel comparison
Participants Number: 57 randomised
Age: not given
Gender: not given
Setting: multicentre
Eligibility criteria: chronic vertigo for at least 3months; 6 attacks in preceding 2months
Exclusion criteria: anti-vertigo drugs and other relevant medications
Baseline characteristics: baseline group comparable for average intensity but otherwise
baseline comparability unclear
Interventions Betahistine up to 48 mg per day for 3 months versus placebo
Intervention group:
n = 27
Comparator group:
n = 20
Use of additional interventions: none
Outcomes Primary outcome: number of patients who improve with respect to vertigo symptoms
Secondary outcomes: 5-point ordinal scale for intensity, patient and physician global
assessment
Funding sources Not given
Declarations of interest 1 co-author affiliated to manufacturer
Notes “No difference” in adverse effects
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Conraux 1988 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, no further information
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants lost to follow-up: 10. Unclear
which groups they belonged to. Analysis is
“as treated”
Selective reporting (reporting bias) High risk Most outcomes not given as raw data or
measures of spread missing
Other bias Unclear risk -
Duphar 77054 1983
Methods Allocation: randomised, but no further detail
Design: prospective, parallel-group, single centre
Participants Number: 50 randomised
Age: up to 70
Gender: 22 M, 14 F
Setting: specialist centre
Eligibility criteria: vertigo “likely to be of peripheral origin”, “stable for 2 or 3 months”
Exclusion criteria: other significant medical conditions (specified in report)
Baseline characteristics: data provided in Table I and Table III of paper
Interventions Betahistine 12 mg 3 times a day versus placebo for 12 weeks
Intervention group:
n = 19
Comparator group:
n = 17
Use of additional interventions: none
Outcomes Primary outcome: vertigo severity (4-point ordinal scale)
Secondary outcomes: adverse effects
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Duphar 77054 1983 (Continued)
Funding sources Unpublished manufacturer data
Declarations of interest Unpublished manufacturer data
Notes Unpublished study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, no further information
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Envelopes provided to participants stating
allocation; returned sealed envelope collec-
tion not reported; opacity not stated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Double blind”, but no further informa-
tion
Incomplete outcome data (attrition bias)
All outcomes
High risk 50 randomised, 33 analysed; betahistine
participants dropped out due to increased
symptoms or high anxiety levelsmaking as-
sessment difficult; analysis is “as treated”
Participants lost to follow-up: 14
Selective reporting (reporting bias) Unclear risk No protocol available for inspection
Other bias Unclear risk No exclusion of participants who had pre-
viously taken betahistine
Duphar H10800580M 1984
Methods Allocation: randomised, but not specified further
Design: prospective, parallel-group, single centre
Participants Number: 40 randomised
Age: 20 to 70
Gender: 17 F 22 M
Setting: ENT hospital department
Eligibility criteria: vertigo attacks with “central signs” on ENG
Exclusion criteria: some medications and neurological disorders
Baseline characteristics: good similarity between groups for severity, duration of disease,
duration of attacks (Table 3.7.1)
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Duphar H10800580M 1984 (Continued)
Interventions 12 weeks betahistine 16 mg 3 times a day versus placebo
Intervention group:
n = 20
Comparator group:
n = 20
Use of additional interventions: none
Outcomes Primary outcome: intensity 5-point ordinal scale
Secondary outcomes: patient and investigator global assessment
Funding sources Unpublished manufacturer data
Declarations of interest Unpublished manufacturer data
Notes Unpublished study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list drawn up before the
start of the study outside treatment centre
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind. Coding envelopes all re-
turned unopened. Opacity not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition and relatively complete
datasets
Participants lost to follow-up: 4
Selective reporting (reporting bias) High risk No data on neuro-otological signs though
these were diagnostic criteria and appear to
have been assessed
Other bias Unclear risk -
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Duphar H10802786F/M 1989
Methods Allocation: randomised, but no further details
Design: prospective, parallel-group, multicentre (5 centres)
Participants Number: 54 randomised, 38 analysed
Age: mean 45.8
Gender: 20 M, 34 F
Setting: 5 centres in France
Eligibility criteria: at least 2 attacks of vertigo of over 2 minutes in the past 3 months
at least 2 weeks apart; vertigo with and without cochlear symptoms
Exclusion criteria: other causes of vertigo, relevant medications
Baseline characteristics: comparable for age, sex, duration of history and time since last
attack
Interventions Betahistine 16 mg 3 times a day versus placebo for 90 days
Intervention group:
n = 27
Comparator group:
n = 27
Use of additional interventions: none
Outcomes Primary outcome: severity on 6-point ordinal scale (0 to 5)
Secondary outcomes: frequency of attacks, severity of attacks, investigator global as-
sessment
Funding sources Manufacturer unpublished data
Declarations of interest Manufacturer unpublished data
Notes Unpublished study - manufacturer supplied data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation in blocks of 4, but sequence
generation method unclear
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants lost to follow-up: 16. Analysis
was “as treated”
34Betahistine for symptoms of vertigo (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Duphar H10802786F/M 1989 (Continued)
Selective reporting (reporting bias) Unclear risk Protocol not available for inspection
Other bias Unclear risk -
Duphar H10803592F 1997
Methods Allocation: randomised in groups of 4 using tables before study started
Design: prospective, parallel, multicentre
Participants Number: 144
Age: 18 to 70
Gender: not specified but groups statistically equal
Setting: French ENT specialist units
Eligibility criteria: recurrent vertigo (at least 2 attacks, at least 1 in last month) including
Ménière’s disease and other
Exclusion criteria: medical and psychiatric disorders (specified), vertigo due to other
causes, contraindication to betahistine
Baseline characteristics: Table 2 shows statistical assessment of similarity
Interventions Betahistine 24 mg twice a day versus placebo for 30 days
Intervention group:
n = 119
Comparator group:
n = 116
Use of additional interventions: none
Outcomes Primary outcome: frequency, severity, duration of attacks
Secondary outcomes: patient and investigator global assessment
Funding sources Unpublished manufacturer study
Declarations of interest Unpublished manufacturer study
Notes Unpublished trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised in groups of 4 before study
started using tables
Allocation concealment (selection bias) Unclear risk Sealed envelopes; opacity not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “neither patient nor investigator knew
which treatment was being given”
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Duphar H10803592F 1997 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants lost to follow-up: 36. Reasons
given for 28 of these
Selective reporting (reporting bias) Low risk Outcomes clearly reported
Other bias Unclear risk Previous trial with betahistine excluded
Duphar H108906NL 1990
Methods Allocation: randomised, no further information
Design: prospective, parallel-group, single centre
Participants Number: 100 randomised
Age: mean 56 (SD 12) in intervention group, mean 53 (SD 16) in placebo group
Gender: 50 F, 24 M
Setting: neurology department, Netherlands
Eligibility criteria: vertigo 3 times a month or chronic
Exclusion criteria: other specified medical conditions and medications. Previous trial
with betahistine
Baseline characteristics: data not given
Interventions Betahistine 16 mg 3 times a day for 8 weeks
Intervention group:
n = 50
Comparator group:
n = 50
Use of additional interventions: none
Outcomes Primary outcome: duration of episodes in seconds, frequency of episodes per month
Secondary outcomes: patient and investigator global opinion
Funding sources Unpublished manufacturer data
Declarations of interest Unpublished manufacturer data
Notes Unpublished study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”; no further information
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Duphar H108906NL 1990 (Continued)
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double blind”; no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double blind”; no further information
Incomplete outcome data (attrition bias)
All outcomes
High risk 11 dropouts in betahistine group and 15
in placebo group; reasons unclear. Analysis
was “as treated”. Participants lost to follow-
up: 26
Selective reporting (reporting bias) High risk Dropout data collected but not reported
Other bias Unclear risk -
Fischer 1985
Methods Allocation: randomised, but no further information
Design: parallel-group
Participants Number: 83 randomised
Age: 18 to 65
Gender: 43 F, 30 M
Setting: Netherlands
Eligibility criteria: episodic vertigo for at least 1 month prior to the beginning of the
study and during this period for at least 2 episodes of dizziness
Exclusion criteria: middle ear infections, cervical vertigo, head injury, cerebrovascular
disease, epilepsy, Parkinson’s,MS, pregnancy, patients on antihistamines, phenothiazines,
vasodilators, barbiturates, tranquillisers
Baseline characteristics: baseline disease duration longer in betahistine group
Interventions Betahistine 16 mg 3 times a day versus placebo for 3 months
Intervention group:
n = 36
Comparator group:
n = 37
Use of additional interventions: none
Outcomes Primary outcome: vertigo intensity (4-point ordinal scale), frequency and duration of
attacks
Secondary outcomes: patient and physician global assessment
Funding sources One co-author affiliated to manufacturer; statistical advice obtained from manufacturer
37Betahistine for symptoms of vertigo (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fischer 1985 (Continued)
Declarations of interest As for funding sources
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”; no further information
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
Incomplete outcome data (attrition bias)
All outcomes
High risk 10 lost after randomisation and not in-
cluded in analysis
Selective reporting (reporting bias) Low risk Appropriate outcomes reported
Other bias Unclear risk -
Guneri 2012
Methods Allocation: randomised, but no further information
Design: parallel-group
Participants Number: 50 analysed
Age: 18 to 79
Gender: 62.5% F, 37.5% M
Setting: university hospital?
Eligibility criteria: benign paroxysmal positional vertigo with positive Dix-Hallpike test
Exclusion criteria: vestibulo-suppressant and ototoxic medications, central nervous sys-
tem disorders and history of previous ear surgery
Baseline characteristics: not stated
Interventions Epley particle repositioning manoeuvre plus betahistine 24 mg twice a day versus Epley
particle repositioning manoeuvre plus placebo over 2 weeks
Intervention group:
n = 24
Comparator group:
n = 26
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Guneri 2012 (Continued)
Use of additional interventions: Epley repositioning manoeuvre used in both groups
equally
Outcomes Primary outcome: Dix-Hallpike positioning tests
Secondary outcomes:Dizziness Handicap Inventory, Vertigo Symptom Scale, Vestibu-
lar Activities of Daily Living Scale, European Evaluation of Vertigo
Funding sources Appropriate disclosures made
Declarations of interest Appropriate disclosures made
Notes Group 1 (Epley manoeuvre only) was discounted for this review as not relevant to review
scope. Potential for bias due to additional intervention is noted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”; no further information
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Physician doing Epley manoeuvre did not
know who would be allocated.” “... sec-
ond physician who supplied medication
was also unaware”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double blind”, but no further informa-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition not mentioned
Participants lost to follow-up: not reported
Selective reporting (reporting bias) High risk Adverse events not reported
Other bias Unclear risk -
Legent 1988
Methods Allocation: randomised, but no further information
Design: parallel-group
Participants Number: 81
Age: not specified
Gender: not specified
Setting: ENT departments, France
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Legent 1988 (Continued)
Eligibility criteria: progressive episodic vertigo with or without cochlear symptoms
Exclusion criteria: central vertigo, BPPV, tumours, CNS disease, iatrogenic, ear disease,
pregnancy, psychiatric disease, asthma, gastrointestinal disease
Baseline characteristics: betahistine group slightly lower intensity and longer duration
of attack scores; raw data not given
Interventions Betahistine 16 mg 3 times a day for 3 months versus placebo
n=59 in total in analysis, but unclear howmany in each group (intervention/comparator)
Use of additional interventions: none
Outcomes Primary outcome: proportion of patients with “good results”
Secondary outcomes: intensity (5-point scale), duration and frequency of attacks, global
patient/doctor rating
Funding sources One co-author affiliated to manufacturer
Declarations of interest One co-author affiliated to manufacturer
Notes Groups “similar at baseline” clinically but data not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”; no further information
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind; no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind; no further information
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants lost to follow-up: 22.Numbers
lost in each treatment arm unclear
Selective reporting (reporting bias) High risk Rawdata for outcomesmissing, e.g. patient
and investigator satisfaction
Other bias Unclear risk -
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Mira 2003
Methods Allocation: 2 randomised lists (one for MD and one for BPPV) generated by the phar-
maceutical company that supplied the drug and placebo tablets, using Fisher and Yates
random number tables
Design: multicentre, parallel-group
Participants Number: 144 randomised
Age: range 18 to 65
Gender: (M:F) betahistine 33:42 placebo 27:42
Setting: 11 university hospitals
Eligibility criteria: Ménière’s disease (probable-possible, AAO-HNS (n = 81); benign
paroxysmal positional vertigo (n = 63)
Exclusion criteria: infections, cerebrovascular disease, drugs that act on cerebral circu-
lation, antihistamines, calcium antagonists, anti-aggregants, thiazide diuretics, corticos-
teroids and benzodiazepines, having any major medical or surgical condition likely to
interfere with the absorption, distribution, metabolism or excretion of the drug used in
the study or having a terminal disease
Baseline characteristics: percentages of patients who had used anti-vertigo drugs slightly
higher in the betahistine group. Baseline data for dizziness scales not given
Interventions Betahistine 16 mg twice a day for 3 months versus placebo
Intervention group:
n = 75
Comparator group:
n = 69
Use of additional interventions: none
Outcomes Primary outcome: number of vertigo attacks per month
Secondary outcomes:Dizziness Handicap Inventory, GISFaV self rating scale, dizziness
assessment rating scale, patient and physician global assessment, adverse events
Funding sources Pharmaceutical company funded, interest declared
Declarations of interest Pharmaceutical company funded, interest declared
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “according to the random list”, “Randomi-
sation in groups of 4”. 2 randomised lists
(one for MD and one for BPPV) generated
by the pharmaceutical company that sup-
plied the drug and placebo tablets, using
Fisher and Yates random number tables
Allocation concealment (selection bias) Low risk As above
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Mira 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “drugs supplied in identical packages with
a fantasy name”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomised patients all accounted for; low
rate of attrition
Participants lost to follow-up: 8
Selective reporting (reporting bias) High risk Raw data frequently not given, only per-
centage change scores which are hard to in-
terpret without baseline data.Dix-Hallpike
test results not given as an outcome for pa-
tients with benign paroxysmal positional
vertigo
Other bias Unclear risk -
Okamoto 1968
Methods Allocation: random number allocation from a table by independent person not con-
nected with the trial
Design: parallel-group
Participants Number: 40 randomised
Age: teens to 70s
Gender: 13 M, 23 F
Setting: specialist unit, Japan
Eligibility criteria: Ménière’s disease (clinically defined)
Exclusion criteria: vertigo due to other causes, e.g. central disorders
Baseline characteristics: similar pre-trial symptom scores
Interventions Betahistine 18 mg twice a day versus placebo over 2 weeks
Intervention group:
n = 18
Comparator group:
n = 18
Use of additional interventions: none
Outcomes Primary outcome: vertigo (3-point ordinal scale)
Secondary outcomes: none
Funding sources Not stated
Declarations of interest Not stated
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Okamoto 1968 (Continued)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number allocation from a table
by independent person not connected with
the trial (James 2001)
Allocation concealment (selection bias) Low risk Independently allocated identical bottles (
James 2001)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
Incomplete outcome data (attrition bias)
All outcomes
High risk 2 (out of 20 randomised) patientswithdrew
from each group, not due to adverse effects
(James 2001)
Participants lost to follow-up: 4
Selective reporting (reporting bias) Low risk Appropriate outcomes reported
Other bias Unclear risk -
Oosterveld 1989
Methods Allocation: randomised, but no further information
Design: cross-over with data extractable before cross-over
Participants Number: 114 randomised
Age: < 65 years old
Gender: 46 F, 36 M
Setting: 18 ENT practices in the Netherlands
Eligibility criteria: episodic vertigo, at least 2 episodes of vertigo in the last month
Exclusion criteria: vertigo secondary to middle/inner ear infection, Parkinson’s, brain
tumour, head trauma, epilepsy, multiple sclerosis or ocular diseases
Baseline characteristics: baseline duration is longer in the placebo group
Interventions Betahistine 16 mg 3 times a day for 10 weeks (5 weeks prior to cross-over)
Intervention group:
n = 38 analysed
Comparator group:
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Oosterveld 1989 (Continued)
n = 44 analysed
Use of additional interventions: none
Outcomes Primary outcome: frequency, duration, severity of attacks (4-point scale)
Secondary outcomes: global rating by patient, unwanted signs and symptoms
Funding sources Not reported
Declarations of interest Not reported. Pharmaceutical company assisted with preparation of report
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”; no further information
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
Incomplete outcome data (attrition bias)
All outcomes
High risk 32 missing/excluded; unclear from which
groups some of them originate
Participants lost to follow-up: 32
Selective reporting (reporting bias) Low risk Appropriate outcomes reported
Other bias Unclear risk -
Otto 2008
Methods Allocation: computer-generated randomisation
Design: parallel-group
Participants 26 with vertigo as part of “vertebrobasilar ischaemia” (see below, clinical diagnosis)
Number: 26 randomised, 22 analysed
Age: 31 to 70
Gender: (M:F) 7:19
Setting: ENT clinic, Germany
Eligibility criteria: vertigo with at least 2 of impaired hearing, impaired vision, tinnitus,
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Otto 2008 (Continued)
headache (“vertebrobasilar ischaemia” according to authors), 2 weeks off anti-vertigo
drugs
Exclusion criteria: other causes of vertigo, other medical conditions (specified)
Baseline characteristics: baseline female predominance in placebo group
Interventions Betahistine 12 mg 3 times a day versus placebo for 4 weeks
Intervention group:
n = 13
Comparator group:
n = 13
Use of additional interventions:none, but study also included a third group treatedwith
fixed combination of cinnarizine and dimenhydrinate, which was the main intervention
of interest to the study authors
Outcomes Primary outcome: vertigo scores (4-point scale)
Secondary outcomes: overall efficacy rated by both patients and investigator on a 5-
point scale
Funding sources Not stated
Declarations of interest 1 co-author affiliated to manufacturer
Notes Study was designed to compare betahistine and placebo with a third comparator group
(fixed proprietary combination of dimenhydrinate and cinnarizine). Only the betahis-
tine/placebo comparison is included in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
Incomplete outcome data (attrition bias)
All outcomes
High risk 15% lost to follow-up in each group
Participants lost to follow-up: 4
Selective reporting (reporting bias) High risk Study was designed for a different purpose
(assessment of the effect of a different drug)
45Betahistine for symptoms of vertigo (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Otto 2008 (Continued)
Other bias Unclear risk -
Ricci 1987
Methods Allocation: “randomisation list”
Design: parallel-group
Participants Number: 10 analysed
Age: mean 36
Gender: 6 M, 4 F
Setting: outpatients, Italy
Eligibility criteria: Ménière’s syndrome, investigator-defined
Exclusion criteria: allergy to betahistine, ulcer, other medical conditions as defined
Baseline characteristics: similar baseline characteristics
Interventions Betahistine 8 mg 3 times a day versus placebo for variable duration (10 x mean duration
of interval between attacks for each patient)
Intervention group:
n = 5
Comparator group:
n = 5
Use of additional interventions: none
Outcomes Primary outcome: narrative only (description of each patient’s history)
Secondary outcomes: none
Funding sources Not stated
Declarations of interest Not stated
Notes Participants lost to follow-up: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation list”
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
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Ricci 1987 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Selective reporting (reporting bias) High risk Limited outcome data and no information
on adverse events
Other bias Unclear risk -
Salami 1984
Methods Allocation: randomised, but no further information
Design: parallel-group
Participants Number: 30 randomised
Age: mean 46 (SD 4)
Gender: 17 M, 13 F
Setting: Italy
Eligibility criteria: Ménière’s disease, clinically defined
Exclusion criteria: other causes of vertigo
Baseline characteristics: groups similar at baseline
Interventions Betahistine 8 mg 3 times a day versus placebo over 6 weeks
Intervention group:
n = 15
Comparator group:
n = 15
Use of additional interventions: none
Outcomes Primary outcome: vertigo intensity on a 4-point scale
Secondary outcomes: vestibular function tests (electronystagmography and caloric test-
ing)
Funding sources Not stated
Declarations of interest Not stated
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”; no further information
Allocation concealment (selection bias) Unclear risk Method not stated
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Salami 1984 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but no further information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but no further information
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition (James 2001)
Selective reporting (reporting bias) Low risk Outcomes and adverse events reported
Other bias Unclear risk -
AAO-HNS: American Academy of Otolaryngology - Head and Neck Surgery
BPPV: benign paroxysmal positional vertigo
CNS: central nervous system
ENG: electronystagmogram
ENT: ear, nose and throat
F: female
M: male
MD: Ménière’s disease
MS: multiple sclerosis
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bertrand 1972 ALLOCATION:
No randomisation
Elia 1966 ALLOCATION:
Quasi-randomised rather than truly randomised
Frew 1976 DESIGN:
Cross-over with data not extractable
Hommes 1972 ALLOCATION:
No randomisation
Meyer 1985 DESIGN:
Cross-over with data not extractable
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(Continued)
NCT00160238 Study terminated early, no data available
NCT00474409 Study terminated early, no data available
Oosterveld 1984 DESIGN:
Cross-over with data not extractable
Purohit 1988 ALLOCATION:
No randomisation
Redon 2011 ALLOCATION:
Randomised controlled trial
PARTICIPANTS:
Participants do not meet inclusion criteria (symptoms of imbalance not vertigo)
Schmidt 1992 ALLOCATION:
Randomised controlled trial
PARTICIPANTS:
Participants do not meet inclusion criteria (symptoms of imbalance not vertigo)
Singarelli 1979 ALLOCATION:
No randomisation
Verspeelt 1996 ALLOCATION:
No randomisation
Watanabe 1967 DESIGN:
Cross-over with data not extractable
Wilmot 1976 DESIGN:
Cross-over with data not extractable
Characteristics of ongoing studies [ordered by study ID]
BEMED
Trial name or title ’Medical treatment of Meniere’s disease with betahistine: a placebo-controlled, dose-finding study’
Methods Placebo-controlled, double-blind, randomised controlled trial
Participants Ménière’s disease
Interventions 1. Therapy with high-dose betahistine (3 x 48 mg)
2. Therapy with low-dose betahistine (2 x 24 mg)
3. Placebo
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BEMED (Continued)
Outcomes Number of vertigo attacks
Median duration of vertigo attacks and median severity of vertigo attacks
Starting date 2007
Contact information Prof M Strupp
Klinikum Grosshadern
Abt. f. Neurologie
Marchioninistrasse 15
Notes Recruitment completed. Data reportedly in analysis (Prof M Strupp, personal communication)
BETAVEST
Trial name or title ’Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind,
placebo-controlled trial’
Methods Double-blind, placebo-controlled trial
Participants Acute unilateral vestibular failure
Interventions Betahistine 24 mg versus placebo
Outcomes Time to recovery from acute symptoms
Starting date 2010
Contact information Prof M Strupp
Klinikum Grosshadern
Abt. f. Neurologie
Marchioninistrasse 15
Notes Ongoing (Prof Strupp, personal communication)
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D A T A A N D A N A L Y S E S
Comparison 1. Betahistine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients with
improvement according to
global judgement of patient:
subgrouped by diagnosis
11 606 Risk Ratio (M-H, Random, 95% CI) 1.30 [1.05, 1.60]
1.1 Ménière’s
(investigator-defined)
3 139 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.92, 2.65]
1.2 BPPV 1 63 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.85, 2.10]
1.3 Other vertigo 8 404 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.97, 1.58]
2 Proportion of patients with
improvement according to
global judgement of patient:
subgrouped by drug dose
11 606 Risk Ratio (M-H, Random, 95% CI) 1.45 [1.09, 1.94]
2.1 Betahistine dose less than
48 mg per day
6 292 Risk Ratio (M-H, Random, 95% CI) 2.11 [1.03, 4.30]
2.2 Betahistine dose 48 mg or
over per day
5 314 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.92, 1.48]
3 Proportion of patients with
adverse effects
12 819 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.76, 1.40]
4 Proportion of patients with
upper gastrointestinal adverse
effects
6 587 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.67, 2.82]
5 Proportion of patients with
headache
4 515 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.15, 5.19]
6 Withdrawal from study 8 481 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.65, 1.42]
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Analysis 1.1. Comparison 1 Betahistine versus placebo, Outcome 1 Proportion of patients with
improvement according to global judgement of patient: subgrouped by diagnosis.
Review: Betahistine for symptoms of vertigo
Comparison: 1 Betahistine versus placebo
Outcome: 1 Proportion of patients with improvement according to global judgement of patient: subgrouped by diagnosis
Study or subgroup Betahistine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 M ni re’s (investigator-defined)
Burkin 1967 5/11 0/11 0.5 % 11.00 [ 0.68, 177.72 ]
Mira 2003 (1) 21/41 12/40 7.7 % 1.71 [ 0.98, 2.99 ]
Okamoto 1968 14/18 11/18 9.6 % 1.27 [ 0.82, 1.98 ]
Subtotal (95% CI) 70 69 17.8 % 1.56 [ 0.92, 2.65 ]
Total events: 40 (Betahistine), 23 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 3.38, df = 2 (P = 0.18); I2 =41%
Test for overall effect: Z = 1.64 (P = 0.10)
2 BPPV
Mira 2003 (2) 22/34 14/29 9.5 % 1.34 [ 0.85, 2.10 ]
Subtotal (95% CI) 34 29 9.5 % 1.34 [ 0.85, 2.10 ]
Total events: 22 (Betahistine), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
3 Other vertigo
Canty 1981 11/15 6/17 5.7 % 2.08 [ 1.02, 4.24 ]
Conraux 1988 19/29 15/21 10.9 % 0.92 [ 0.63, 1.34 ]
Duphar 77054 1983 18/19 15/17 14.6 % 1.07 [ 0.88, 1.32 ]
Duphar H10800580M 1984 15/20 5/19 4.9 % 2.85 [ 1.29, 6.30 ]
Duphar H108906NL 1990 18/36 15/34 8.6 % 1.13 [ 0.69, 1.87 ]
Fischer 1985 33/36 32/37 15.4 % 1.06 [ 0.90, 1.25 ]
Oosterveld 1989 27/38 25/44 12.0 % 1.25 [ 0.90, 1.74 ]
Otto 2008 9/11 0/11 0.6 % 19.00 [ 1.24, 291.01 ]
Subtotal (95% CI) 204 200 72.7 % 1.24 [ 0.97, 1.58 ]
Total events: 150 (Betahistine), 113 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 22.07, df = 7 (P = 0.002); I2 =68%
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 308 298 100.0 % 1.30 [ 1.05, 1.60 ]
Total events: 212 (Betahistine), 150 (Placebo)
0.005 0.1 1 10 200
Favours placebo Favours betahistine
(Continued . . . )
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(. . . Continued)
Study or subgroup Betahistine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.07; Chi2 = 30.84, df = 11 (P = 0.001); I2 =64%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Chi2 = 0.62, df = 2 (P = 0.73), I2 =0.0%
0.005 0.1 1 10 200
Favours placebo Favours betahistine
(1) Meniere’s subgroup
(2) BPPV subgroup
Analysis 1.2. Comparison 1 Betahistine versus placebo, Outcome 2 Proportion of patients with
improvement according to global judgement of patient: subgrouped by drug dose.
Review: Betahistine for symptoms of vertigo
Comparison: 1 Betahistine versus placebo
Outcome: 2 Proportion of patients with improvement according to global judgement of patient: subgrouped by drug dose
Study or subgroup Betahistine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betahistine dose less than 48 mg per day
Burkin 1967 5/11 0/11 1.0 % 11.00 [ 0.68, 177.72 ]
Canty 1981 12/15 5/17 7.1 % 2.72 [ 1.25, 5.93 ]
Duphar 77054 1983 18/19 15/17 13.6 % 1.07 [ 0.88, 1.32 ]
Mira 2003 54/75 21/69 11.6 % 2.37 [ 1.61, 3.47 ]
Okamoto 1968 14/18 11/18 10.8 % 1.27 [ 0.82, 1.98 ]
Otto 2008 9/11 0/11 1.0 % 19.00 [ 1.24, 291.01 ]
Subtotal (95% CI) 149 143 45.1 % 2.11 [ 1.03, 4.30 ]
Total events: 112 (Betahistine), 52 (Placebo)
Heterogeneity: Tau2 = 0.53; Chi2 = 47.17, df = 5 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.05 (P = 0.040)
2 Betahistine dose 48 mg or over per day
Conraux 1988 19/29 15/21 11.6 % 0.92 [ 0.63, 1.34 ]
0.005 0.1 1 10 200
Favours placebo Favours betahistine
(Continued . . . )
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(. . . Continued)
Study or subgroup Betahistine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Duphar H10800580M 1984 15/20 5/19 7.0 % 2.85 [ 1.29, 6.30 ]
Duphar H108906NL 1990 18/36 15/34 10.1 % 1.13 [ 0.69, 1.87 ]
Fischer 1985 33/36 32/37 13.9 % 1.06 [ 0.90, 1.25 ]
Oosterveld 1989 27/38 25/44 12.2 % 1.25 [ 0.90, 1.74 ]
Subtotal (95% CI) 159 155 54.9 % 1.16 [ 0.92, 1.48 ]
Total events: 112 (Betahistine), 92 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.64, df = 4 (P = 0.07); I2 =54%
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 308 298 100.0 % 1.45 [ 1.09, 1.94 ]
Total events: 224 (Betahistine), 144 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 53.44, df = 10 (P<0.00001); I2 =81%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 2.41, df = 1 (P = 0.12), I2 =58%
0.005 0.1 1 10 200
Favours placebo Favours betahistine
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Analysis 1.3. Comparison 1 Betahistine versus placebo, Outcome 3 Proportion of patients with adverse
effects.
Review: Betahistine for symptoms of vertigo
Comparison: 1 Betahistine versus placebo
Outcome: 3 Proportion of patients with adverse effects
Study or subgroup Betahistine group Placebo group Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Burkin 1967 0/11 0/11 Not estimable
Canty 1981 0/15 0/17 Not estimable
Conraux 1988 4/29 5/21 6.7 % 0.58 [ 0.18, 1.90 ]
Duphar 77054 1983 5/19 4/17 7.3 % 1.12 [ 0.36, 3.50 ]
Duphar H10800580M 1984 0/20 0/19 Not estimable
Duphar H10803592F 1997 25/119 25/116 39.1 % 0.97 [ 0.60, 1.59 ]
Duphar H108906NL 1990 10/50 12/50 17.2 % 0.83 [ 0.40, 1.75 ]
Fischer 1985 0/36 0/37 Not estimable
Mira 2003 21/75 15/69 28.5 % 1.29 [ 0.72, 2.29 ]
Okamoto 1968 0/18 0/18 Not estimable
Otto 2008 5/11 0/11 1.2 % 11.00 [ 0.68, 177.72 ]
Salami 1984 0/15 0/15 Not estimable
Total (95% CI) 418 401 100.0 % 1.03 [ 0.76, 1.40 ]
Total events: 70 (Betahistine group), 61 (Placebo group)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.72, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours betahistine
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Analysis 1.4. Comparison 1 Betahistine versus placebo, Outcome 4 Proportion of patients with upper
gastrointestinal adverse effects.
Review: Betahistine for symptoms of vertigo
Comparison: 1 Betahistine versus placebo
Outcome: 4 Proportion of patients with upper gastrointestinal adverse effects
Study or subgroup Betahistine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Conraux 1988 4/29 2/21 17.2 % 1.45 [ 0.29, 7.19 ]
Duphar 77054 1983 2/19 2/17 13.4 % 0.89 [ 0.14, 5.68 ]
Duphar H10803592F 1997 7/119 1/116 10.8 % 6.82 [ 0.85, 54.60 ]
Duphar H108906NL 1990 7/50 7/50 37.8 % 1.00 [ 0.38, 2.64 ]
Mira 2003 2/75 3/69 14.6 % 0.61 [ 0.11, 3.56 ]
Otto 2008 4/11 0/11 6.2 % 9.00 [ 0.54, 149.50 ]
Total (95% CI) 303 284 100.0 % 1.38 [ 0.67, 2.82 ]
Total events: 26 (Betahistine), 15 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 5.74, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours betahistine Favours placebo
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Analysis 1.5. Comparison 1 Betahistine versus placebo, Outcome 5 Proportion of patients with headache.
Review: Betahistine for symptoms of vertigo
Comparison: 1 Betahistine versus placebo
Outcome: 5 Proportion of patients with headache
Study or subgroup Betahistine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Duphar 77054 1983 0/19 1/17 18.0 % 0.30 [ 0.01, 6.91 ]
Duphar H10803592F 1997 6/119 11/116 36.5 % 0.53 [ 0.20, 1.39 ]
Duphar H108906NL 1990 0/50 2/50 18.8 % 0.20 [ 0.01, 4.06 ]
Mira 2003 11/75 1/69 26.7 % 10.12 [ 1.34, 76.35 ]
Total (95% CI) 263 252 100.0 % 0.88 [ 0.15, 5.19 ]
Total events: 17 (Betahistine), 15 (Placebo)
Heterogeneity: Tau2 = 2.02; Chi2 = 8.61, df = 3 (P = 0.03); I2 =65%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours betahistine Favours placebo
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Analysis 1.6. Comparison 1 Betahistine versus placebo, Outcome 6 Withdrawal from study.
Review: Betahistine for symptoms of vertigo
Comparison: 1 Betahistine versus placebo
Outcome: 6 Withdrawal from study
Study or subgroup Betahistine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Duphar 77054 1983 6/25 6/23 16.0 % 0.92 [ 0.35, 2.45 ]
Duphar H10800580M 1984 1/20 3/19 3.2 % 0.32 [ 0.04, 2.79 ]
Duphar H10802786F˙x002f˙M 1989 8/27 8/27 22.7 % 1.00 [ 0.44, 2.28 ]
Duphar H108906NL 1990 14/50 16/50 42.6 % 0.88 [ 0.48, 1.60 ]
Mira 2003 6/75 2/69 6.3 % 2.76 [ 0.58, 13.22 ]
Okamoto 1968 2/20 2/20 4.4 % 1.00 [ 0.16, 6.42 ]
Otto 2008 2/13 2/13 4.7 % 1.00 [ 0.16, 6.07 ]
Salami 1984 0/15 0/15 Not estimable
Total (95% CI) 245 236 100.0 % 0.96 [ 0.65, 1.42 ]
Total events: 39 (Betahistine), 39 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.87, df = 6 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours betahistine Favours placebo
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL PubMed EMBASE (Ovid)
#1 MeSH descriptor: [Dizziness] explode
all trees
#2 MeSH descriptor: [Vertigo] explode all
trees
#3MeSHdescriptor: [MeniereDisease] ex-
plode all trees
#1 “Dizziness”[Majr]
#2 “Vertigo”[Mesh]
#3 “Meniere Disease”[Mesh]
#4 (vertig* or bppv or meniere* or vestibu-
lar or endolymphatic and hydrops or
1 *dizziness/
2 exp vertigo/
3 exp Meniere disease/
4 (vertig* or bppv or meniere* or vestibu-
lar or (endolymphatic and hydrops) or
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(Continued)
#4 vertig* or bppv or meniere* or vestibu-
lar or (endolymphatic and hydrops) or
(labyrinth and hydrops) or (labyrinth and
syndrome) or (cochlea and hydrops)
#5 lightheaded* or imbalance or disorien-
tat* or dizzy or dizziness or (self next mo-
tion) or (illusion* near movement*)
#6 #1 or #2 or #3 or #4 or #5
#7MeSH descriptor: [Betahistine] explode
all trees
#8 BETAHISTIN* or BETAISTINA or
SERC or AEQUAMEN or BETASERC
or BETASERK or BEATSERKA or EX-
TOVYL or FIDIUM or LECTIL or LO-
BIONE or MEGINALISK or MELOPAT
or MENIACE or MERISLON or MI-
CROSER or RIBRAIN or VASOMOTAL
or (BY next vertin)
#9 #7 or #8
#10 #6 and #9
(labyrinth and hydrops) or (labyrinth and
syndrome) or (cochlea and hydrops))
#5 (lightheaded* or imbalance or disorien-
tat* or dizzy or dizziness or (self and mo-
tion) or (illusion* and movement*))
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 “Betahistine”[Mesh]
#8 (BETAHISTIN* or BETAISTINA or
SERC or AEQUAMEN or BETASERC
or BETASERK or BEATSERKA or EX-
TOVYL or FIDIUM or LECTIL or LO-
BIONE or MEGINALISK or MELOPAT
or MENIACE or MERISLON or MI-
CROSER or RIBRAIN or VASOMOTAL
or “BY vertin” or BY-vertin)
#9 #7 OR #8
#10 (#9 AND #6)
(labyrinth and hydrops) or (labyrinth and
syndrome) or (cochlea and hydrops)).tw
5 (lightheaded* or imbalance or disorien-
tat* or dizzy or dizziness or (self adj6 mo-
tion) or (illusion* adj6 movement*)).tw
6 1 or 2 or 3 or 4 or 5
7 exp betahistine/
8 (BETAHISTIN* or BETAISTINA or
SERC or AEQUAMEN or BETASERC
or BETASERK or BEATSERKA or EX-
TOVYL or FIDIUM or LECTIL or LO-
BIONE or MEGINALISK or MELOPAT
or MENIACE or MERISLON or MI-
CROSER or RIBRAIN or VASOMOTAL
or (BY adj6 vertin)).tw
9 7 or 8
10 6 and 9
CINAHL (EBSCO) Web of Science (Web of Knowledge) Trial Registries
S1 (MM “Dizziness”)
S2 (MH “Vertigo”)
S3 (MH “Endolymphatic Hydrops+”) OR
(MH “Meniere’s Disease”)
S4 TX vertig* or bppv or meniere* or
vestibular or (endolymphatic and hydrops)
or (labyrinth and hydrops) or (labyrinth
and syndrome) or (cochlea and hydrops)
S5 TX lightheaded* or imbalance or dis-
orientat* or dizzy or dizziness or (self n6
motion) or (illusion* n6 movement*)
S6 S1 OR S2 OR S3 OR S4 OR S5
S7 TX BETAHISTIN* or BETAISTINA
or SERC or AEQUAMEN or BETASERC
or BETASERK or BEATSERKA or EX-
TOVYL or FIDIUM or LECTIL or LO-
BIONE or MEGINALISK or MELOPAT
or MENIACE or MERISLON or MI-
CROSER or RIBRAIN or VASOMOTAL
or (BY n6 vertin)
S8 S6 AND S7
#1 TS=(vertig* or bppv or meniere* or
vestibular or (endolymphatic and hydrops)
or (labyrinth and hydrops) or (labyrinth
and syndrome) or (cochlea and hydrops))
#2 TS=(lightheaded* or imbalance or dis-
orientat* or dizzy or dizziness or (self and
motion) or (illusion* and movement*))
#3 #2 OR #1
#4 TS=(BETAHISTIN* or BETAISTINA
or SERC or AEQUAMEN or BETASERC
or BETASERK or BEATSERKA or EX-
TOVYL or FIDIUM or LECTIL or LO-
BIONE or MEGINALISK or MELOPAT
or MENIACE or MERISLON or MI-
CROSER or RIBRAIN or VASOMOTAL
or “by vertin” or by-vertin)
#5 #4 AND #3
ClinicalTrials.gov
(vertigo OR vertiginous OR bppv ORme-
niere ORmenieresOR vestibular OR dizzy
OR dizziness) AND (betahistine OR be-
tahistin OR serc OR betaserc)
ICTRP
betahistine AND Meniere* OR serc AND
Meniere* OR betahistine and vertigo* OR
serc AND vertigo* OR dizziness AND be-
tahistine OR dizziness AND serc OR dizzy
AND betahistine OR dizzy AND serc OR
vestibular AND betahistine OR vestibular
AND serc OR bppv AND betahistine OR
bppv AND serc
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added ’withdrawal from study’ as an outcome measure in addition to proportion of patients with adverse effects.
We have promoted ’Proportion of patients with adverse effects’ from a secondary to a primary outcome measure.
We removed ’double-blinded’ from the inclusion criteria for types of studies. Level of blinding was dealt with in our ’Risk of bias’
assessments, as is standard practice.
We have described the GRADE methodology and process for creating the ’Summary of findings’ table in the Methods section.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Benign Paroxysmal Positional Vertigo [drug therapy]; Betahistine [adverse effects; ∗therapeutic use]; Randomized Controlled Trials as
Topic; Vertigo [∗drug therapy]
MeSH check words
Humans
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